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ROLE OF microRNA-709 IN MURINE LIVER 
 
MicroRNA are small RNA molecules that regulate expression of genes involved 
in development, cell differentiation, proliferation and death. It has been estimated that in 
eukaryotes, approximately 0.5 to 1% of predicted genes encode a microRNA, which in 
humans, regulate at least 30% of genes at an average of 200 genes per miRNA. Some 
microRNAs are tissue-specific, while others are ubiquitously expressed. In liver, a few 
microRNAs have been identified that regulate specialized functions. The best known is 
miR-122, the most abundant liver-specific miRNA, which regulates cholesterol 
biosynthesis and other genes of fatty acid metabolism; it also regulates the cell cycle 
through inhibition of cyclin G1. To discover other miRNAs with relevant function in 
liver, we characterized miRNA profiles in normal tissue and identified miR-709. Our data 
indicates this is a highly abundant hepatic miRNA and is dysregulated in an animal 
model of type 2 diabetes. To understand its biological role, miR-709 gene targets were 
identified by analyzing the transcriptome of primary hepatocytes transfected with a miR-
709 mimic. The genes identified fell within four main categories: cytoskeleton binding, 
extracellular matrix attachment, endosomal recycling and fatty acid metabolism. Thus, 
similar to miR-122, miR-709 downregulates genes from multiple pathways. This would 
be predicted, given the abundance of the miRNA and the fact that the estimated number 
of genes targeted by a miRNA is in the hundreds. In the case of miR-709, these suggested 
a coordinated response during cell proliferation, when cytoskeleton remodeling requires 
substantial changes in gene expression. Consistently, miR-709 was found significantly 
vii 
upregulated in an animal model of hepatocellular carcinoma. Likewise, in a mouse model 
of liver regeneration, mature miR-709 was increased. To study the consequences of 
depleting miR-709 in quiescent and proliferating cells, primary hepatocytes and 
hepatoma cells were cultured with antagomiRs (anti-miRs). The presence of anti-miR-
709 caused cell death in proliferating cells. Quiescent primary hepatocytes responded by 
upregulating miR-709 and its host gene, Rfx1. These studies show that miR-709 targets 
genes relevant to cystokeleton structural genes. Thus, miR-709 and Rfx1 may be needed 
to facilitate cytoskeleton reorganization, a process that occurs after liver injury and 
repopulation, or during tumorigenesis. 
 
Núria Morral, Ph.D., Chair 
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INTRODUCTION 
 
A. Role of liver in metabolism 
The liver is the largest metabolic organ in the human body
8
. Various metabolic 
pathways occurring in this tissue, including carbohydrate metabolism (gluconeogenesis, 
glycolysis, glycogenesis, glycogenolysis), lipid metabolism (cholesterol and triglyceride 
synthesis and export, fatty acid oxidation, ketogenesis) and protein metabolism (synthesis 
and degradation), are essential for whole body homeostasis (Figure 1). Finally, the liver 
produces bile, which is critical for emulsification of lipids and aids in digestion of lipids 
in the small intestine.  
 
Maintaining blood glucose levels within a narrow range is vital for the body, both 
in periods of feeding and fasting. This important function of glucose homeostasis is 
carried out by hepatocytes in the liver. Upon feeding, glucose is broken down into 
pyruvate through glycolysis to produce energy for the cells. In addition, excess glucose is 
taken up by the liver and converted into glycogen (glycogenesis). In periods of fasting, 
the glycogen stores in the liver are used to produce glucose (glycogenolysis); in addition, 
the liver synthesizes glucose from amino acids, glycerol, and lactate, through the 
gluconeogenesis pathway.   
 
The liver also plays an important role in lipid metabolism. In the fed state, excess 
glucose is converted into fatty acids (de novo lipogenesis) and subsequently esterified 
into triglycerides, which remain as droplets in the cytoplasm or can be secreted from the 
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liver into the circulation via very low-density lipoprotein (VLDL) for use by other 
tissues. In the fasted state, the liver can actively oxidize fatty acids to produce ketone 
bodies that are exported into circulation, thereby providing an alternate energy source for 
other organs in the body, in particular for the brain. The liver also synthesizes cholesterol, 
lipoproteins and phospholipids. Some of the cholesterol is converted into bile salts. In 
addition to cholesterol, the bile contains organic and inorganic solutes that make up 5% 
of the bile
9
. The apical membranes of adjacent hepatocytes form a canalicular network 
through which bile is secreted from the hepatocytes
9
. Bile synthesis is regulated by 
transport systems localized on the apical membrane of hepatocytes
9
.   
 
Protein metabolism is another important function of the liver. This tissue 
synthesizes non-essential amino acids and makes most of the plasma proteins such as 
albumin and clotting factors. The liver is also involved in breakdown of amino acids by 
deamination and transamination, and removes ammonia from the bloodstream, 
converting it into urea for excretion. 
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Figure 1. Metabolic pathways in liver. Source: Adapted from image obtained from 
http://www.elmhurst.edu/~chm/vchembook/600glycolysis.html 
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B. Liver organization 
The liver is a complex organ with at least 15 different cell types
8
. Hepatocytes 
comprise approximately 60% of the cells and take up 80% of the volume in the liver, 
while sinusoidal endothelial cells (SEC), Kupffer cells and hepatic stellate cells represent 
20%, 15% and 5% of cells, respectively
8
. Each of these four major cellular types has 
specific functions. Hepatocytes, in particular, play important roles in maintaining lipid 
and glucose homeostasis.  
 
The liver’s blood supply is one of its kind; it receives venous blood from the 
portal vein, as well as oxygenated blood from the hepatic artery
8
. The blood from these 
vessels flows through the liver sinusoids, a highly branched discontinuous network of 
blood vessels, before it is delivered to the hepatocytes
8
. Hepatocytes are arranged into 
hexagonal lobules, the liver’s functional unit (Figure 2 and 3). At the center of the lobule 
is a central vein. The central veins from multiple lobules combine to form the hepatic 
vein, which eventually joins the inferior vena cava. At the junction of several lobules is a 
portal triad, consisting of branches of hepatic artery, hepatic portal vein and interlobular 
bile ducts. Hepatocytes closer to the entering vascular supply (periportal) receive the 
most oxygenated blood while hepatocytes close to the central vein (perivenous) receive 
the least oxygenated blood. This results in a metabolic zonation, wherein the amount of 
liver enzymes and their activities vary in periportal and perivenous hepatocytes
10
. 
Periportal hepatocytes are rich in enzymes such as phosphoenolpyruvate carboxykinase 
(PCK), glucose 6-phosphatase (G6Pase) (carbohydrate metabolism), HMG-CoA 
reductase (HMGCR) (lipid metabolism) and glutamic-pyruvate transaminase (GPT), 
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glutathione peroxidase (GPX) (amino acid metabolism)
10
. Periportal hepatocytes are 
specialized in oxidative functions such as β-oxidation of fatty acids, gluconeogenesis, 
bile formation and cholesterol synthesis
10
. Also, sub-cellular organelles such as 
mitochondria and bile canaliculi are more abundant in periportal hepatocytes compared to 
perivenous hepatocytes
10
. On the other hand, perivenous hepatocytes are abundant in 
enzymes such as glucokinase (GK), pyruvate kinase (PKL) (carbohydrate metabolism), 
Acetyl-coA carboxylase (ACC), ATP-dependent citrate lysase (ACL), fatty acid synthase 
(FAS) (lipid metabolism), glutamine synthetase (GNS) (amino acid metabolism) and 
cytochrome P450 (P450), UDP glucuronate transferease (UDPGT) (xenobiotic 
metabolism)
10
. These hepatocytes are preferentially involved in glucose uptake for 
glycogen synthesis, glycolysis, lipogenesis, and detoxification
10
.  
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Figure 2. Liver cross section. The arrangement of sinusoids, hepatocytes and bile 
canaliculi is shown. Source: Image from
8
.  
 
 
Figure 3. Liver lobule and portal triad.  
(Source: Image from http://en.wikipedia.org/wiki/File:Hepatic_structure.png) 
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C. Hepatocyte polarity and cytoskeletal organization  
The liver is known second after brain for its complexity in structure and 
function
11
. Hepatocytes are the major cell type in the liver, comprising 80% of the 
volume
11
. Like all epithelial cells, hepatocytes must be polarized with well-defined apical 
and basolateral membranes to be functional
12,13
. The apical and basal surfaces are 
separated by tight junctions
8
 (Figure 4). Specific functions are performed depending on 
the polarity (apical versus basolateral domain) of the hepatocytes
14
. Each of these 
domains is characterized by specific marker proteins. Hepatic apical or canalicular 
membrane is characterized by expression of proteins such as Breast Cancer Resistance 
Protein (Bcrp), Bile Salt Export Pump (Bsep), Multidrug resistance-associated protein 2 
(Mrp2), multidrug resistance gene 1 (Mdr1) and multidrug resistance gene 2 (Mdr2) 
whereas basolateral markers include Multidrug resistance-associated protein 1 (Mrp1), 
Multidrug resistance-associated protein 3 (Mrp3), Multidrug resistance-associated protein 
6 (Mrp6), Multidrug resistance-associated protein 2 (Mrp4) and Na/Taurocholate 
Cotransporting Polypeptide (Ntcp)
13
. Bile canaliculi are formed on the apical membrane 
of two adjacent hepatocytes and bile acid transporters are confined to this domain
14,15
. 
The basolateral surface of hepatocytes is involved in trafficking of metabolites from the 
bloodstream
14
. Hepatocytes constantly internalize extracellular ligands and other 
materials by endocytosis
16,17
. The endocytosed products are either recycled back to the 
cell surface, destined for lysosomal degradation, or undergo transcytosis to the opposite 
membrane
8,16
 (Figure 5). These are mediated by very dynamic and diverse endosomal 
compartments
17
.  
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Receptors bound to their ligands at the basolateral membrane are taken up into 
early endosomes and are separated from their ligand
17,18
. This occurs at the periphery of 
the cell. The receptor can then recycle back while the ligand destined for degradation has 
to pass through late endosomes, pre-lysosomes, or multivesicular bodies (MVBs) before 
being delivered to the lysosomes
17
. Substrates of apical proteins are also endocytosed and 
transported from the basolateral membrane to the apical membrane of the hepatocyte, and 
are then released into the bile canaliculi
18
. Many of the apical proteins synthesized in the 
cell are first sent to the basolateral membrane before being transported to their final 
destination, the apical membrane
18
. This emphasizes the importance of endocytosis in 
hepatocytes.  
 
The extracellular matrix (ECM) of the liver plays a vital role in endocytosis. It is 
primarily made up of type I collagen and is crucial for hepatic function
11
. The ECM 
comprises many elements such as matrix metalloproteinases; the glycoproteins laminin, 
fibronectin, vitronectin, undulin, nidogen (entactin); and proteoglycans such as heparan 
sulfate
11
. Recently, miRNAs have been shown to play a key role in regulating the 
expression of ECM proteins. miR-29 targets key ECM proteins such as laminin, nidogen 
and fibrillin and members of miR-29 family have been shown to be downregulated in 
liver fibrogenesis. miR-199 is upregulated during fibrogenesis and targets matrix 
metalloproteinases and collagen proteins. This highlights the importance of miRNAs in 
maintaining the ECM of hepatocytes, which is critical for hepatic polarity. 
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Figure 4. Hepatocyte polarity. BC, Bile canaliculi; +++ Basolateral membrane; - - - 
Apical membrane. (Source: Modified from
13
).  
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Figure 5. Endosomal recycling in hepatocytes. Steps 1, 2, and 3: Receptor mediated 
endocytosis of receptor bound to ligand. Step 4: Ligand is separated from the receptor in 
early endosome. 5, 6, and 7: Ligand is either degraded in lysosome or transported into 
bile canaliculi depending on the final destination of the ligand. Step 8: Receptor is 
recycled back to the cell surface. Steps I, II, and III: Recycling ligand is endocytosed in 
clathrin coated vesicles. Steps IV, V, VI, VII, and VIII: The ligand is recycled back to the 
cell surface.(Source: Adapted from
18
) 
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D. MicroRNAs 
MicroRNAs (miRNAs) are a class of small non-coding RNAs that are highly 
conserved
19
 and are widely expressed in plants, animals, and some viruses. Mature 
miRNAs are typically 18-25 nucleotides in length and these regulate gene expression 
post-transcriptionally
20
. It has been estimated that the human genome encodes over 1,000 
miRNAs
21
, which may target about 60% of mammalian genes
22
. Over 1,800 murine 
mature miRNAs have been identified so far (www.miRBase.org). miRNAs modulate 
gene function post-transcriptionally by either specific inhibition of translation or 
induction of target mRNA cleavage
23
. A single miRNA can target multiple mRNA 
targets, and each mRNA can be targeted by many miRNAs
20
. This feature allows 
miRNAs to alter multiple gene expression regulatory networks
20
. Initial studies on 
miRNA biology indicated that miRNAs regulate their targets mostly at the protein 
synthesis level and regulate gene expression by mRNA degradation to a lower extent. 
However, there is increasing evidence that miRNAs target mRNA to a larger extent than 
initially thought
24
, and most of the miRNA-mediated repression on its targets is caused 
by mRNA destabilization as opposed to the prior scenario of ‘translational-
repression’24,25.  
 
MiRNA processing. miRNA genes are mostly transcribed by RNA polymerase II, 
although some are transcribed by RNA polymerase III
26,27
. The primary miRNA 
transcript (pri-miRNA) is synthesized in the nucleus of cells and is polyadenylated and 
capped, similar to messenger RNAs
20,28,29
. The pri-miRNA contains regions that are not 
perfectly complementary, forming a stem-loop structure. In mammals, this pri-miRNA 
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undergoes further processing by two ribonuclease (RNase) III family members: Drosha 
and Dicer
28
. The pri-miRNA is cleaved by the complex consisting of Drosha and co-
factor DiGeorge syndrome critical region gene 8 (DGCR8), to form precursor miRNA 
(pre-miRNA)
20,28
. The pre-miRNA, a 60-100 nucleotides long hairpin structure, is then 
exported from the nucleus into the cytoplasm by the Exportin 5 (XPO5)/Ran-GTP 
complex
20,28
. In the cytoplasm, Dicer and TAR RNA binding protein (TRBP) then cleave 
off the loop from the pre-miRNA structure leaving behind an 18-25 nucleotides long 
dsRNA duplex
20,28
. This duplex is comprised of a guide strand and a passenger strand, 
each of which has a different purpose in the cell
28
. The guide strand is taken up by 
Argonaute (AGO) to form the Argonaute-containing miRNA-induced silencing complex 
(miRISC)
20
 while the passenger stand is degraded
28. miRISC can then bind to the 3’ 
untranslated region (UTR) of target mRNAs by partial base pairing and lead to mRNA 
degradation or translational repression
20,30-35
 (Figure 6). 
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Figure 6. Processing of miRNA. The primary miRNA transcript (pri-miRNA) is 
transcribed by RNA polymerase II or III. The pri-miRNA is then cleaved by the 
microprocessor complex Drosha – DGCR8 (Pasha) to pre-miRNA in the nucleus. The 
precursor hairpin, pre-miRNA, is then exported from the nucleus to the cytoplasm by 
Exportin-5 – Ran-GTP. In the cytoplasm, the RNase Dicer along with the double-
stranded RNA-binding protein TRBP cleaves the pre-miRNA hairpin to form a miRNA 
duplex. The mature strand of the miRNA is then loaded together with Argonaute (Ago) 
proteins into the RNA-induced silencing complex (RISC), where it guides RISC to 
silence target mRNAs through mRNA cleavage, translational repression or mRNA 
deadenylation. The passenger strand from the miRNA duplex is degraded. DGCR8, 
DiGeorge syndrome critical region gene 8. TRBP, TAR RNA binding protein (Source: 
Adapted from
36
). 
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Repression of gene expression. The nucleotides in positions 2-8 from the 5’ end of the 
guide strand represent the ‘seed’ region20,37 (Figure 7). It is an important feature in 
miRNA target recognition and mutations in the seed region lead to changes in target 
specificity and/or disease
38-40
. In plants, perfect pairing of a miRNA with its target 
mRNA leads to recruitment of deadenylation factors to remove the poly(A) tail of the 
target mRNA and endonucleolytic cleavage of the mRNA
20,28,41,42
. In mammals, the 
miRISC mostly induces gene silencing by imperfect matching of nucleotides between the 
miRNA and its target RNAs, leading to repression of protein synthesis and/or mRNA 
degradation through deadenylation and decapping
28
. Translational repression occurs 
through interference with factors required for translation such as eukaryotic translation-
initiation factor 4G (eIF4G) and poly(A)-binding protein (PABPC)
43
. After extensive 
speculation about the stage at which translational repression occurs (initiation versus 
post-initiation stage), recent data has proved that repression occurs predominantly during 
initiation of translation
43
. Deadenylation of mRNAs involves the CAF1-CCR4-NOT 
deadenylase complex, and mRNA-decapping enzyme 2 (DCP2), a decapping enzyme 
decaps the target mRNA, resulting in mRNA degradation by exoribonuclease 1 (XRN1), 
the major 5’-to-3’ exonuclease in cultured cells43. However, this is not true in cellular 
extracts. In cell extracts, deadenylated mRNAs are thought to remain undegraded in a 
deadenylated, translationally repressed state
43
. Irrespective of the mode of action of the 
miRNA, the miRISC complexes along with the bound target mRNAs are found enriched 
in processing bodies (P-bodies or GW-bodies), cytoplasmic structures containing mRNA 
degrading enzymes and are implicated in the storage and degradation of the target 
mRNAs
23
.  
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Figure 7. Structural components of a pre-miRNA. The pre-miRNA is composed of a 
stem-loop structure comprising the guide strand, passenger strand, additional sequences, 
and the loop. The guide strand is shown in red and the seed sequence is highlighted in 
black. 
 
Gene regulation by miRNAs is also controlled by RNA binding proteins. RNA 
binding proteins interacting with the 3’ UTR of miRNA target mRNAs can reverse or 
augment the inhibition by certain miRNAs
23
. Under stress conditions, inhibition of CAT-
1 mRNA by miR-122 is relieved by the protein HuR, which translocates from the nucleus 
to the cytoplasm and binds to the 3’ UTR of the CAT-1 mRNA, causing the CAT-1 
mRNA to leave the P-body and bind to polysomes
23,44
. 
 
Several groups have recently reported that miRNAs can also activate gene 
expression of its targets, in addition to inhibit expression
23
. One example is miR-122, 
which has been shown to upregulate the levels of Hepatitis C Virus (HCV) RNA through 
binding to its 5’ UTR23. Also, miR-10a has been shown to increase translation of mRNAs 
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with 5’ TOP motifs by binding to the 5’ UTR downstream of the 5’ TOP motif23,45. 
Recent data shows that translational activation by miRNAs may be mediated through 
AGO2-containing complexes under serum starvation conditions and during cell cycle 
arrest
45
.  
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E. Role of miRNAs in liver  
Given that miRNAs are largely transcribed by RNA polymerase II, their 
expression is subject to transcriptional regulation in a similar manner to protein-encoding 
genes. Thus, the metabolic state of a cell can influence the expression of a single or 
multiple miRNAs, and miRNA expression profiles have been found to be altered in 
various metabolic disorders such as diabetes and obesity
28
. In a study comparing miRNA 
expression profiles between skeletal muscle of normal and diabetic rats, 4 miRNAs were 
found up-regulated and 11 miRNAs were found down-regulated
46
. This may suggest that 
miRNAs play a key role in metabolism and can in fact be potential diagnostic and 
prognostic markers
28,47
. 
 
Dicer1, the only RNase III family member in mammals for processing dsRNA 
into both miRNAs and siRNAs
48
, is critical for miRNA maturation from early postnatal 
liver, and its deletion results in profound hepatocyte apoptosis, steatosis and mild 
hypoglycemia
37
. This implies that miRNAs have critical roles in normal liver 
development and physiology. It is now widely accepted that miRNAs have important 
regulatory roles in various cellular processes. Recent work has implicated miRNAs in 
pancreas development and insulin secretion
49
, as well as insulin sensitivity in liver
50
. It 
has also been shown that miRNAs play a role in various hepatic metabolic functions such 
as fatty acid and cholesterol metabolism, insulin signaling and glucose metabolism. 
 
miRNA-10b (miR-10b) was identified in L02 cells, a human model of hepatic 
steatosis
28,51
. Overexpression of miR-10b resulted in triglyceride and lipid accumulation 
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in these cells by directly targeting peroxisome proliferator-activated receptor-α (PPAR-
α), a nuclear receptor involved in lipid metabolism28,51. This study provided a novel 
mechanism by which miR-10b regulated hepatic steatosis in the context of non-alcoholic 
fatty liver disease (NAFLD).  
 
miRNA-122 (miR-122) is the most abundant liver-specific miRNA and has been 
implicated in various metabolic processes important for hepatic function and liver 
pathology
52
. miR-122 is almost solely expressed in hepatocytes
53
 and represents roughly 
70% of the total miRNAs expressed in the adult liver
54
. miR-122 is expressed in mouse 
and human livers, primary hepatocytes and liver-derived cell lines such as Hepa1-6 and 
Huh7 cells
54
. miR-122 has been shown to bind to the 3’ UTR of cationic amino acid 
transporter-1 (CAT-1) mRNA
44,54,55
. miR-122 has been shown to play roles in fatty acid 
metabolism and cholesterol metabolism
52
 through downregulation of 1-Acylglycerol-3-
Phosphate O-Acyltransferase 1 (AGPAT1) and Cell Death-Inducing DFFA-Like Effector 
C (CIDEC). Silencing miR-122 in mice fed a high-fat diet resulted in a significant 
reduction of hepatic steatosis
56
. This was also seen with a notable decrease in serum 
cholesterol levels
54,56
.  
 
miR-122 has also been involved in the pathophysiology of hepatocellular 
carcinoma (HCC). It acts as a tumor suppressor and is downregulated in 70% of  HCC 
cases
57
. This is mediated by upregulation of miR-122 targets such as Cut-like homeobox 
1 (CUTL1), A disintegrin and metalloprotease family 17 (ADAM17) and cyclin G1
57
. 
Other targets of miR-122 involved in hepatocarcinogenesis that have been recently found 
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are: A disintegrin and metalloprotease family 10 (ADAM10)
52
, insulin-like growth factor 
1 receptor (IGF1R)
52
, N-Myc Downstream-Regulated Gene 3 (NDRG3)
58
 and 
Microtubule-Associated Protein, RP/EB Family, Member 1 (MAPRE1)
59
. Overall, this 
suggests that miR-122 and its targets have an integral role in liver development and 
function
52
 (Figure 8). 
 
Figure 8. Role of miR-122 in liver
52
. The figure illustrates the role of miR-122 in the 
liver. miR-122 inhibits expression of CAT-1, ADAM10, Igf1R, Mapre1, NDGR3 and is 
found downregulated in hepatocellular carcinoma. miR-122 prevents hepatocellular 
carcinoma through inhibiting cyclin G1 and preventing the association of cyclin G1 with 
p53. miR-122 has also been shown to play a role in cholesterol and lipid metabolism.  
 
miRNA-216 (miR-216) and miRNA-302a (miR-302a) were found 
downregulated in livers of hypercholesterolemic low-density lipoprotein receptor 
(LDLR) knockout mice that were fed a high-fat diet compared to those that were fed a 
chow diet
28,60
. Also, this study found an inverse correlation between the levels of miR-
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302a and its target genes ABCA1 transporter and ELOVL fatty acid elongase 6 
(ELOVL6), a microsomal enzyme involved in the formation of long-chain FA
28,60
. This 
suggests a role for miR-302a in fatty acid, cholesterol and glucose metabolism
60
. 
 
miRNA-33a/b (miR-33a/b) are the best example of intronic miRNAs that work 
together with their host genes to regulate cholesterol and fatty acid metabolism. miR-33a 
is co-transcribed with sterol-regulatory element  binding protein 2 (SREBP-2) gene
61
, a 
transcription factor important in de novo cholesterol synthesis and uptake
62
, while miR-
33b is co-transcribed with sterol-regulatory element binding protein 1  (SREBP-1), a 
transcription factor involved in fatty acid synthesis
61,63,64
. In vivo studies in mice and non-
human primates have both shown that inhibition of miR-33a/b using different approaches 
resulted in increased hepatic expression of miR-33 target gene, adenosine triphosphate-
binding cassette (ABC) transporter member 1 (ABCA1), a transporter that reduces 
cholesterol efflux to high-density lipoprotein (HDL)
65,66
. This increase in expression of 
ABCA1 resulted in elevated HDL levels in mouse and non-human primate animal 
models
65,66
. Other cholesterol metabolism genes targeted by miR-33a are ATP-binding 
cassette sub-family G member 1 (ABCG1) and Niemann-Pick disease, type C1 (NPC1)
67
. 
miR-33b has been shown to target genes involved in fatty acid metabolism such as 
carnitine palmitoyltransferase 1a (CPT1a), carnitine O-octaniltransferase (CROT), 
hydroxyacyl-CoA-dehydrogenase (HADHB), AMP kinase subunit-α (AMPK1α) and 
reduce fatty acid oxidation
67
.  
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In addition, miR-33 has also been shown to have a negative role in regulating insulin 
signaling by acting on insulin receptor substrate-2 (IRS-2) and reducing downstream 
signaling
28,67
 in human hepatocellular carcinoma cell lines HepG2 and Huh7.  
 
miRNA-34a (miR-34a) was found upregulated in livers of patients with nonalcoholic 
steatohepatitis (NASH)
28,68
. miR-34a directly inhibits sirtuin 1 (SIRT)-1, leading to 
downstream activation of HMGCoA reductase (HMGCR) which, in turn results in 
elevated levels of cholesterol in these patients
28,69
.   
 
miRNA-335 (miR-335) was found upregulated in livers and white adipose tissues 
(WAT) of three animal models of obesity – db/db, ob/ob and KKAy mice70. This was 
associated with elevated hepatic triglyceride and cholesterol levels suggesting that miR-
335 may represent a biomarker for hepatic lipid accumulation in mice
47,70
.  
 
miRNA-370 (miR-370) has been shown to be a potent regulator of lipid metabolism 
in HepG2 cells
71
. miR-370 regulates genes involved in fatty acid and triglyceride 
synthesis such as transcription factor sterol-regulatory element binding protein 1c 
(SREBP-1c), diacylglycerol acyltransferase-2 (DGAT2), fatty acid synthase (FAS), and 
acyl-CoA carboxylase 1 (ACC1) through upregulating miR-122
28,71
. miR-370 directly 
targets the 3’ UTR of carnitine palmitoyl transferase 1a (Cpt1a), a mitochondrial enzyme 
involved in shuttling fatty acids into mitochondria for -oxidation
28,71
. This implies that 
miR-370 may be implicated in the accumulation of triglycerides in the liver by increasing 
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the expression of miR-122 (thereby increasing de novo -
oxidation
71
.  
 
miRNA-467b (miR-467b) was shown to be downregulated in livers of mice fed a 
high-fat diet and in steatotic hepatocytes
72
. miR-467b was found to regulate the 
expression of hepatic lipoprotein lipase (LPL), an enzyme that hydrolyzes 
triglycerides
28,72
. This interaction between miR-467b and LPL has been associated with 
insulin resistance and plays an important role in the spectrum of NAFLD.  
 
In addition to miR-122 (see page 18), other miRNAs have been consistently 
found downregulated in hepatocellular carcinoma (HCC). MicroRNAs miR-199a-1, miR-
199a-2 and miR-199b have been shown to be downregulated in HCC, which results in 
upregulation of targets such as MET (Met Proto-Oncogene), mTOR (Mammalian Target 
Of Rapamycin), CD44 (CD44 Molecule) and HIF-1α (Hypoxia Inducible Factor 1, Alpha 
Subunit)
57
. This causes HCC to be highly proliferative, invasive and resistant to radiation. 
On the other hand, miR-221 is upregulated in HCC and results in downregulation of 
genes involved in cell cycle inhibition, negative regulation of the mTOR pathway, pro-
apoptosis, as well as inhibition of metalloproteases
57
.    
 
Overall, these studies highlight the possibility that pharmacological inhibition of 
miRNAs may become a therapeutic strategy for the treatment of hepatic diseases. 
Identification of miRNA targets therefore becomes an important aspect of developing 
new miRNA-based therapeutic products. Despite the emerging role of miRNAs at 
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controlling genes important in liver metabolism, the mechanisms by which miRNA 
regulate physiological responses is still poorly understood. 
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F. Thesis hypothesis and research aims  
The liver is an important organ regulating many metabolic processes and is responsible 
for various critical functions in the body. In recent years, differential expression of 
miRNAs has been observed in many disease states. Thus, the development of molecules 
to inhibit miRNAs that are found upregulated in particular diseases can be exploited for 
therapeutic purposes. Likewise, targeting deleterious genes with miRNAs represents an 
attractive therapeutic strategy. Thus, understanding the mechanisms by which miRNAs 
govern hepatic functions is key for developing novel therapeutic agents. I proposed to 
identify miRNAs differentially expressed in murine liver under pathological or 
nutritionally distinc conditions, to understand the role of miRNA in the pathophysiology 
of type 2 diabetes, and on vital hepatic functions. My central hypothesis was that miRNA 
that are dysregulated may affect expression of target genes, and contribute to the 
development of that disorder. Using primary hepatocytes as a cellular model, my central 
hypothesis was tested by pursuing the following specific aims: (i) To identify miRNAs 
dysregulated in livers of an animal model of type 2 diabetes, and in the transition from 
the fasted to refed state; (ii) To identify gene targets of mmu-miR-709 (miR-709); (iii) To 
determine the biological role of miR-709 in murine liver. 
 
Specific Aim 1: To identify miRNAs dysregulated in livers of an animal model of 
type 2 diabetes, and in the transition from the fasted to refed state.  
The working hypothesis for Aim 1 was that expression of hepatic miRNAs are altered in 
metabolic disorders such as diabetes. Also, miRNAs are largely transcribed by RNA 
polymerase II and therefore, may be transcriptionally regulated like protein-encoding 
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genes. Identifying these miRNA and understanding their function in the liver will help 
understand the mechanisms that lead to hepatic disorders and developing novel therapies. 
This hypothesis was tested by conducting miRNA microarrays on liver tissues from 
normal and db/db mice, and from fasted and refed animals. 
 
Specific Aim 2: To identify gene targets of miR-709. The working hypothesis for Aim 
2 was that mRNAs directly regulated by a miRNA should be downregulated upon 
transient transfection of miRNA mimics. I checked mRNA profiles of primary 
hepatocytes transfected with miR-709 and confirmed the expression of its targets at 
protein level. Identifying the targets of miR-709 enabled the characterization of the 
pathways regulated by miR-709 in the murine liver.  
 
Specific Aim 3: To determine the biological role of miR-709 in murine liver. The 
abundance of miR-709 in murine liver, its predicted and confirmed targets, suggested an 
important role for miR-709 in cell proliferation. This hypothesis was tested by analyzing 
miR-709 in animal models of liver regeneration and liver cancer and by studying the 
impact of depleting miR-709 during cell division. 
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MATERIALS AND METHODS 
 
A. MATERIALS  
A.1. Plasmids. psiCHECK
TM
-2 Luciferase vector (Promega, Madison, WI) was used to 
generate p.miR-709-3p, p.miR-709-5p, p.Rab11b, p.Ces1g, p.Pctp, p.NC-Rab11b, p.NC-
Ces1g and p.NC-Pctp constructs. pBluescript II SK(+) vector (Stratagene, CA, USA) was 
used to generate plasmid p.pri-Cel-239b.  
 
A.2. Primers 
Table 1. Oligonucleotides used to generate luciferase constructs and 
primers used for qRT-PCR (5’  3’). 
Oligonucleotides 
Pctp TATGCACTCGAGCATCTGGATTTTTCCTTTCCC 
ATCAGGCGGCCGCGGTGGTACACGCCTTTAATC 
NC- Pctp TATGCACTCGAGTCAGGCTTCAAAGATGGCTTG 
AATCAGGCGGCCGCCTGAGTTCGAGGCTAACCTG 
Ces1g TATGCACTCGAGTCAATCGTCTGACACCAGTG 
AATCAGGCGGCCGCTTCTAAGGGAATGTATTTGTGA
T 
NC-Ces1g TATGCACTCGAGGAGCCAAGGAAACAGCAGAG 
ATCAGGCGGCCGCTCCAGGAAAGCCAGGACTAC 
Rab11b ATGCACTCGAGCAGGGTTTCTCTGTGTAGC 
TCAGGCGGCCGCGAGGGGCAAGGGTGTCTT 
NC-Rab11b ATGCACTCGAGCCAGGAAGAGCAGGAGTCC 
ATCAGGCGGCCGCGAGTTTGGGATGAGGATACAG 
Cel-239b 
primary 
transcript 
CCAGTGTCCCACAGAGTAATTAGTGTGTAGCGACTA
AACACATCAACTCAGAAGTGCTCTA 
AGCTTAGAACTGTCCAGTTTGAGCAGCACTGGTTGA
TGTGTTTAGTCGCTATTGTCTTTTGTTATATTGACTT
ATGCTGCA 
Primers used for qRT-PCR 
CD36 GGCAAAGAACAGCAGCAAAATC  
TGAAGGCTCAAAGATGGCTCC 
Gck CACTGCGGAGATGCTCTTTGAC 
CCACGATGTTGTTCCCTTCTGC 
Acox2 GAATAACAGTTGGGGACATAGG 
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CTGGAGGGTGGGTAGGAATC 
Pfkl GCAAGGTATGAATGCTGCTGTC 
TGGAAACGCTGAGCCAGTTGG 
Pctp CAAGAAGGGGAGCAGAGAATGG 
TGGTGTAGCACAGCCAGAGATG 
Rab11b CAAAGTGGTGCTTATTGGGGAC 
CTGAGCCTTGATGGTCTTGCC 
Ces1g TGTAAAACCACCACCTCCGCTG 
TCTCTGGGGTCTCCAAGAAAATC 
TBP TATCACTCCTGCCACACCAG 
CATGATGACTGCAGCAAATCG 
 
A.3. Mice. Animals were purchased from The Jackson Laboratory (Bar Harbor, ME). 
Animal studies were performed in compliance with Indiana University School of 
Medicine Institutional Animal Care and Use Committee guidelines. 
A.3.1. Liver miRNA analysis: Four 12-week old, male C57BLKS/J and db/db mice (an 
obese animal model of type 2 diabetes lacking a functional leptin receptor), were used to 
study hepatic miRNA expression profiles under fed conditions (see section B.6.a).  
A.3.2. Primary hepatocyte isolation: Male C57BL/6J mice (11 to 12 weeks old, 24 to 
30g) were used for isolation of primary hepatocytes. Mice were fed rodent chow ad 
libitum and allowed free access of water. A standard 12 h light/12 h dark cycle (7 AM/7 
PM) was maintained throughout the experiments. Mice were allowed to acclimate for at 
least a week before experimentation. 
A.3.3. miRNA profiles under fed, fasted, refed conditions: Fifteen 14-week old, male 
C57BL/6J mice were used for studying the expression of miRNAs under different 
nutritional status (see section B.6.b).  
A.3.4. Relative expression of pre-miR-709 vs mature miR-709: Livers from normal 
LapMyc mice (5 male and 2 female) and tumor LapMyc mice (5 male) were obtained 
from Dr. Janaiah Kota (Department of Medical and Molecular Genetics, Indiana 
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University School of Medicine)
59
. Livers from normal C57BL/6 male mice before 
hepatectomy, and 24, 36 and 44 hours post-hepatectomy (3 animals per group) were 
provided by Dr. Guoli Dai (Department of Biology, Purdue University School of 
Science)
73
.  
 
A.4. Antibodies 
Table 2. Antibodies used for Western blotting. 
Antibody Manufacturer Dilution factor 
Rab11b  Cell Signaling, Boston, MA 1:1,000 
DYNC1LI1 GeneTex, San Antonio, TX 1:1,000 
Glucokinase (N-term) Abgent, San Diego, CA 1:500 
Insulin receptor-  Santa Cruz Biotechnology, 
Dallas, TX 
1:500 
LDLR Abcam, Cambridge, MA 1:3000 
FATP1 Santa Cruz Biotechnology, 
Dallas, TX 
1:500 
Timp3 Santa Cruz Biotechnology, 
Dallas, TX 
1:1000 
Cyclophilin 40 Abcam, Cambridge, MA 1:1000 
Tubulin-α Ab-2 (Clone DM1A) Thermo Scientific, Rockford, 
IL 
1:10,000 
β-actin (C4) Santa Cruz Biotechnology, 
Dallas, TX 
1:500 
Anti-rabbit IgG, HRP-linked  Cell Signaling, Boston, MA 1:3,000 - 1:5,000 
 
A.5. Other reagents 
A.5.a. Plasmid isolation. Plasmid mini kit (Qiagen, Valencia, CA) and plasmid maxi kit 
(Qiagen, Valencia, CA) was used for small scale (~3 ml LB broth) and large scale (~200 
ml LB broth) plasmid isolation, respectively. 
A.5.b. RNA isolation. Total RNA Isolation from cells and tissues for RT-PCR:  
RNAeasy mini/midi kit (Qiagen, Valencia, CA), RNAse free-DNAse I (Qiagen, 
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Valencia, CA) and β-mercaptoethanol were used to isolate total RNA. Total RNA 
Isolation from cells and tissues for Taqman miRNA assay and Northern blot of miRNAs: 
the long (>200 bp) and miRNA-enriched (<200 bp) RNA fractions were isolated using 
mirVana
TM
 miRNA Isolation kit (Ambion, Life Technologies, Grand Island, NY). 
A.5.c. Protein isolation. RIPA buffer (25 mM Tris•HCl pH 7.6, 150 mM NaCl, 1% NP-
40, 1% sodium deoxycholate, 0.1% SDS; Thermo Scientific, Rockford, IL) containing 
protease and phosphatase inhibitors (Roche, Indianapolis, IN) was used to lyse cells and 
isolate proteins. 
A.5.d. DNA gel extraction. QIAEX II Gel Extraction Kit (Qiagen, Valencia, CA) was 
used to isolate PCR product fragments from agarose gels. 
A.5.e. Ligation. T4 DNA ligase (New England Biolabs, Ipswich, MA) was used to ligate 
PCR products into psiCHECK
TM
-2 Luciferase vector according to manufacturer’s 
instructions. 
A.5.f. PCR. High Capacity cDNA reverse transcription kit (Applied Biosystems, Life 
Technologies, Grand Island, NY) was used to generate cDNA from mouse liver.  
A.5.g. qRT-PCR. QuantiTect SYBR Green RT-PCR kit (Qiagen, Valencia, CA) was 
used, following the manufacturer's recommendations. Reactions were set up in 96-well 
Optical reaction plates covered with optical caps (Applied Biosystem, Foster City, CA). 
Real time PCR was performed using an ABI Prism 7500 instrument (Applied Biosystem, 
Foster City, CA). 
A.5.h. TaqMan miRNA assay. TaqMan miRNA Reverse Transcription Kit (Applied 
Biosystems, Foster City, CA) was used to generate cDNA, followed by PCR with 
TaqMan miRNA Assays (Applied Biosystems) specific for miR-709 and sno-202. 
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A.5.i. Protein quantification. Pierce® BCA Protein Assay Kit (Thermo Scientific, 
Hanover Park, IL) was used to quantify proteins. 
A.5.j. Western Blot detection. Pierce® ECL Western Blotting Substrate (Thermo 
Scientific, Hanover Park, IL) was used to detect proteins. 
A.5.k. LDH assay. Cytotoxicity LDH Detection Kit (Clontech, Mountain View, CA) was 
used for detection of lactate dehydrogenase (LDH).  
A.5.l. Transfection. METAFECTENE® PRO (Biontex, Germany) was used as 
transfection reagent at lipid:DNA ratios described in the cell transfection section.  
A.5.m. LB broth. Luria-Bertani (LB) broth (Sigma, St. Louis, MO) was used to grow E. 
coli (Escherichia coli) bacteria. 
A.5.n. Bacteria for subcloning. XL1-Blue Subcloning grade competent cells (Agilent, 
Santa Clara, CA) were used for transformation of plasmids.  
A.5.o. Cell lines. The mouse hepatoma cell line Hepa-1c1c7 and human embryonic 
kidney cell line HEK293 were obtained from American Type Culture Collection 
(ATCC).  
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B. METHODS 
B.1. Plasmid cloning. p.miR-709-3p and p.miR-709-5p constructs were generated by 
cloning an oligonucleotide with a sequence perfectly complementary to either the 3’ or 
the 5’ strand of miR-709 (based on the sequence published in TargetScan), downstream 
of the renilla luciferase gene in plasmid psiCHECK
TM
-2 Luciferase vector (Promega, 
Madison, WI) (Figure 9). Oligonucleotides (Invitrogen, Life Technologies, Grand Island, 
NY) were inserted into the NotI – XhoI site using Quick ligation kit (New England 
Biolabs, Ipswich, MA). These plasmids were used to determine whether the 3’ or 5’ 
strand is the guide strand of miR-709.  
 
Figure 9. Schematic representation of the psiCHECK
TM
-2 plasmid used for 
generating constructs for luciferase reporter assays. All sequences were cloned using 
Not I and Xho I sites into the 3’ UTR of the Renilla luciferase cDNA. 
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Tough decoys (TuDs) to reduce cellular levels of miR-709 and miR-122, were 
generated by cloning 8 copies of the sequence complementary to the 3p strand of miR-
709 or the 5p strand of miR-122, downstream from the luciferase gene in psiCHECK
TM
-
2. The sequence inserted was chemically synthesized (GenScript, NJ, and Genewiz, NJ) 
with XhoI and NotI sites at the ends to facilitate cloning. 
 
To confirm that Rab11b, Ces1g and Pctp are direct targets of miR-709, 220-720 
base-pair (bp) fragments of the 3’ UTR containing the putative binding sites 
(microrna.org
74
), were cloned in the NotI – XhoI site of psiCHECKTM-2 vector. Total 
mRNA from mouse liver was used to generate the cDNA (High Capacity cDNA reverse 
transcription kit, Applied Biosystems, Life Technologies, Grand Island, NY) and the 
corresponding portion of the 3’ UTR of Rab11b, Ces1g and Pctp was amplified by PCR 
using primers with restriction sites for NotI – XhoI (Table 1). The PCR products were 
digested with XhoI and NotI, gel purified with QIAEX II Gel Extraction Kit (Qiagen, 
Valencia, CA) and cloned into psiCHECK
TM
-2, generating plasmids p.Rab11b, p.Ces1g 
and p.Pctp. In addition, a portion of the 3’ UTR of these mRNAs without miR-709 
binding sites was cloned into psiCHECK
TM
-2 and used as negative controls (p.NC-
Rab11b, p.NC-Ces1g and p.NC-Pctp). Clones were sequenced prior to using them in 
luciferase assays. 
 
A plasmid expressing the primary transcript of miR-709 (p.pri-miR-709) was 
purchased from OriGene (Rockville, MD, USA). p.pri-miR-709 is composed of pre-miR-
709 (88 nt) and 250-300 nt flanking genomic sequence (Figure 10A). The flanking 
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sequence is required for correct pri-miR expression and processing by the microprocessor 
complex (Drosha). As control, p.pri-Cel-239b was cloned into pBluescript II SK(+) 
vector (Stratagene, CA, USA) in 4 steps (Figure 10B). The promoter, polyA signal and 
300 bp flanker regions were obtained by PCR amplification from the p.pri-miR-709 
plasmid and thus, have the same sequence. The pre-Cel-239b sequence was chemically 
synthesized as 4 oligonucleotides that anneal to form the appropriate restriction enzyme 
sites on either end. All clones were sequenced prior to using them in experiments.  
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Figure 10. Schematic representation of plasmids expressing pri-miR-709 and pri-
Cel-239b. (A) Plasmid expressing pri-miR-709 (OriGene). (B) Plasmid expressing pri-
Cel-239b miRNA was generated as described in the text.
(A) 
(B) 
35 
 
B.2. Primary hepatocyte isolation. Primary hepatocytes were isolated using a two-step 
collagenase procedure, as previously described
75
. Briefly, mice were anesthetized with 
pentobarbital (90 mg/kg body weight i.p.) and the liver was perfused with Ca
2+
 and Mg
2+
 
free Hank’s Balanced Salt solution (HBSS) containing 5 mM ethylene glycol tetraacetic 
acid (EGTA) and 0.05 M HEPES. This was followed by perfusion with 0.075% 
collagenase solution in DMEM. After perfusion, the liver was cut out and liver cells were 
dispersed in 15 ml collagenase solution using forceps. Cells were filtered through a 70-
µm nylon mesh and centrifuged at 100xg for 5 min to pellet hepatocytes. The cell pellet 
was washed in 20 ml DMEM with 10% FBS and centrifuged again. To enrich for live 
cells, the cell pellet was resuspended in 25 ml DMEM (without FBS) plus 24 ml 90% 
Percoll solution
76
. Cell viability was assessed by trypan blue staining exclusion (>80% 
viability). Cells were seeded at a density of 4-6x10
5
 cells per well or 35-mm dish in 2 ml 
DMEM supplemented with 10% (v/v) fetal bovine serum (FBS), 100 I.U./ml penicillin, 
100 µg/ml streptomycin, 3 nM insulin and 1 nM dexamethasone. Cells were incubated at 
37°C, 5% CO2 in a humidified incubator and allowed to attach for 4 hours. Media was 
then replaced with fresh media.  
 
B.2.a. Primary hepatocyte sandwich
77
 experiments. For primary hepatocyte sandwich 
experiments, 6x10
5
 cells were plated on collagen-coated glass-bottom 35-mm dishes 
(MatTek, Ashland, MA). Media was replaced 4 hours post-plating and cells were 
transfected with 34 nM of miR-709 or the control miRNA Cel-239b (Dharmacon, 
Pittsburgh, PA). The next day, primary hepatocytes were overlaid with BD Matrigel
TM
 
(BD Biosciences, San Jose, CA) at a final concentration of 0.25 mg/ml in cold DMEM 
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supplemented with 10% (v/v) fetal bovine serum, 100 I.U./ml penicillin, 100 µg/ml 
streptomycin and 100 nM dexamethasone. Cells were cultured for 3-5 days to allow the 
formation of bile canalicular networks between cells. Media was replaced every day.  
 
B.2.b. Sodium fluorescein assay. Four hours after plating, mouse primary hepatocytes 
were transfected with 34 nM miR-709 or Cel-239b (Dharmacon, Lafayette, CO), 
siRab11b-1 and siRab11b-2, or siNC (Invitrogen, Life Technologies). Cells treated with 
siRab11b-1 and siRab11b-2 received equimolar concentrations of siRab11b-1 and 
siRab11b-2 for a final concentration of 30 nM. Next morning, media was aspirated and 2 
ml of 0.25 mg/ml Matrigel
TM
 (BD Biosciences, San Jose, CA, USA) in DMEM 
supplemented with 10% FBS, 100 I.U./ml penicillin, 100 µg/ml streptomycin and 100 
nM dexamethasone was added to all wells. Twenty-four hours later, media was replaced. 
Seventy-two hours post-transfection, cells were washed twice with media I (150 mM 
NaCl, 20 mM HEPES, 1 mM CaCl2, 5 mM KCl, 1 mM MgCl2, and 10 mM glucose) and 
sodium fluorescein was added at 4 μM in media I. Cells were then incubated at 37°C in 
incubator for 10 min. The cells were washed twice with media I and 2 ml of DMEM 
supplemented 10% FBS, 100 I.U./ml penicillin, 100 µg/ml streptomycin and 100 nM 
dexamethasone, was added. Cells were again incubated for 10 min at 37°C in a CO2 
incubator. Images were taken at specified time points.  
 
B.2.c. Imaging of labeled miR-709 in primary hepatocytes. For imaging experiments, 
6x10
5
 cells were plated on collagen-coated glass-bottom 35-mm dishes (MatTek, 
Ashland, MA). Media was replaced 4 hours post-plating. Next day, cells were transfected 
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with 34 nM of 3’ FAM labeled miR-709 or the control miRNA Cel-67 labeled with 
Dy547 (Dharmacon, Pittsburgh, PA). Twenty-four hours later, media was replaced and 4 
drops of Hoechst 33342 (NucBlue® Live ReadyProbes® Reagent; Molecular probes) 
was added to each well and incubated at 37°C in a 5% CO2 incubator for 20 mins. 
Samples were then imaged by confocal fluorescence microscopy on an inverted 
microscope fitted with an FV1000 MPE using a 60x 1.2 NA water immersion objective 
lens (Olympus). Imaging was performed sequentially with excitation provided by solid 
state lasers at 405 and 559 nm and an Argon-ion laser at 488 nm; emission was collected 
with spectral filtration from 425-475 nm, 500-545 nm or filter based from 575-675 nm, 
respectively. Confocal slices were taken at 0.49 micron intervals with voxel dimensions 
of 0.265 x 0.265 microns. All post-acquisition analysis was performed in Fiji v1.48p
78
 
and figure generation was performed in Photoshop (Adobe). 
 
B.3. Cell culture. Mouse hepatoma Hepa1c1c7 cells were cultured in MEM-α 
supplemented with 10% FBS and 100 I.U./ml penicillin, 100 µg/ml streptomycin and 
were plated in 6-well plates at a cell density of 1-5x10
5
 cells/well in 2 ml media.  
 Human embryonic kidney HEK293 cells were cultured in MEM-α supplemented 
with 10% FBS and 100 I.U./ml penicillin, 100 µg/ml streptomycin and were plated in 6-
well plates at a cell density of 6x10
5
 cells/well in 2 ml media.  
 
B.3.a. Imaging of labeled miR-709 in Hepa1c1c cells. For imaging experiments, 4x10
5
 
cells were plated on collagen-coated glass-bottom 35-mm dishes (MatTek, Ashland, 
MA). Media was replaced 5 hours post-plating and cells were transfected with 34 nM of 
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miR-709 or the control miRNA Cel-67 (Dharmacon, Pittsburgh, PA). Next day, media 
was replaced and samples were imaged by confocal fluorescence microscopy on an 
inverted Olympus microscope fitted with an FV1000 MPE using a 60 x 1.2 NA water 
immersion objective lens (Olympus). A second set of samples was imaged 24 hours after 
culturing them in media without FBS and glucose (metabolic stress conditions). Imaging 
was performed sequentially with excitation provided by solid state lasers at 405 and 559 
nm and an Argon-ion laser at 488 nm; emission was collected with spectral filtration 
from 425-475 nm, 500-545 nm or filter based from 575-675 nm, respectively.  Confocal 
slices were taken at 0.49 micron intervals with voxel dimensions of 0.265 x 0.265 
microns. All post-acquisition analysis was performed in Fiji v1.48p
78
 and figure 
generation was performed in Photoshop (Adobe). 
 
B.3.b. LDH assay in Hepa1c1c cells. For lactate dehydrogenase (LDH) release 
experiments, 4.5 x10
5
 cells were plated on 6-well plates. Media was replaced 16 hours 
post-plating and cells were transfected with 25 nM or 50 nM of anti-miR-709 or anti-
control-miR. The next day, media was replaced. One-hundred μls of media was collected 
before and 24, 48 and 72 hours post-transfection, and LDH release was quantified.    
 
B.4. Cell transfection  
B.4.a. Using plasmids and miRNA: Mouse primary hepatocytes or Hepa1c1c7 cells 
were transfected with plasmids (1.5 µg) together with 34 nM of miR-709 or the control 
miRNA Cel-239b (Dharmacon). Transfection was performed at a nucleic acid:lipid ratio 
of 1:6. Cells were incubated at 37°C in a 5% CO2 incubator. After overnight incubation, 
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media was replaced with fresh media. Cells were harvested 24 hours later and analyzed 
for luciferase activity using the dual-luciferase® reporter assay system (Promega) and a 
luminometer (Centro LB 960 microplate luminometer, Berthold Technologies). Renilla 
luciferase activity was normalized to firefly luciferase expressed from the same 
psiCHECK
TM
-2 plasmid. 
 
B.4.b. Using plasmids: HEK293 cells or Hepa1c1c7 cells were transfected with 1.5 µg 
plasmids expressing pri-miR-709 or pri-Cel-239b. Transfection was performed at a 
nucleic acid:lipid ratio of 1:4. Cells were incubated at 37°C in a 5% CO2 incubator. After 
overnight incubation, media was replaced with fresh media. Cells were harvested 24 
hours later and RNA was isolated for analyzing miR-709 expression.  
 
B.4.c. Using miRNA/siRNA/antagomiRs/anti-miRs: Four hours or the next morning 
after plating, mouse primary hepatocytes were transfected with 34 nM miR-709 
(Dharmacon, Lafayette, CO), Cel-239b, siRab11b-1 (MSS208343), siRab11b-2 
(MSS208345), siRab11b-1 and siRab11b-2, control siRNA (siNC, 12935-300, 
Invitrogen, Life Technologies) using Metafectene Pro (1:6 ratio). Cells treated with 
siRab11b-1 and siRab11b-2 received equimolar concentrations of siRab11b-1 and 
siRab11b-2 for a final concentration of 30 nM. Media was replaced 24 hours later and 
cells were harvested 48 hours post-transfection to analyze protein expression. For 
antagomiRs/anti-miRs, mouse primary hepatocytes or Hepa1c1c cells were transfected 
with 10, 17, 25, 34 or 50 nM of anti-miR-709, or anti-control-miR using Metafectene Pro 
(1:6 ratio). Media was replaced 24 hours later and cells were harvested 24 hours post-
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transfection to analyze mRNA or miR-709 expression or were maintained in culture upto 
72 hours for LDH assay. 
 
B.5. miRNA target predictions. Multiple databases (miRanda
74
, miRDB
79,80
, 
miRWalk
81
, TargetScan
82
, DIANAmT
83,84
, miRBase
85-91
, PICTAR5
92
 and RNA22
93
) 
were used to predict targets of mmu-miR-709 (Mus musculus miRNA-709).  
 
B.6. Array analyses. 
B.6.a. miRNA microarray: miRNA chip analysis was conducted by LC Sciences 
(Houston, TX). Four animals per group (normal and db/db) were used. The RNA of two 
mice from one group was labeled with Cy3 and the RNA from the other two animals was 
labeled with Cy5. One wild type and one db/db sample was used to hybridize each of 
four chips. Background was determined using a regression-based background mapping 
method. The regression was performed on 5% to 25% of the lowest intensity data points 
excluding blank spots. Raw data matrix was then subtracted from the background matrix. 
Normalization was carried out using a LOWESS (Locally-weighted Regression) method 
on the background-subtracted data. Transcripts were considered detectable if they met at 
least two conditions: signal intensity higher than 3x background standard deviation; and 
spot CV <0.5. CV was calculated by standard deviation (SD)/signal intensity. A 
transcript was listed as detectable only if the signals from at least 50% of the repeating 
probes were above detection level. Data adjustment included data filtering, log2 
transformation, and gene centering and normalization. The data filtering removed 
miRNAs with (normalized) intensity values below a threshold value of 32 across all 
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samples. The log2 transformation converts intensity values into log2 scale. Gene 
centering and normalization transform the log2 values using the mean and the standard 
deviation of individual genes across all samples. A t-test was performed between normal 
and diabetic sample groups. T-values were calculated for each miRNA, and p-values 
were computed from the theoretical t-distribution. miRNAs with p-values below 0.01 
were selected for cluster analysis. The clustering was done using a hierarchical method 
and was performed with average linkage and Euclidean distance metric. 
 
B.6.b. mRNA Affymetrix analysis: Four replicates for miR-709 and three replicates for 
Cel-239b were used. The quality of RNA was determined by Agilent 600 
Nanobioanalyzer. mRNA microarray hybridization was performed by the Center for 
Medical Genomics, at Indiana University School of Medicine. Affymetrix mouse gene 
1.0 ST arrays were used to compare expression of about 28,850 genes using one chip per 
replicate. Briefly, samples were labeled using the standard Affymetrix protocol for the 
WT Target Labeling and Control Reagents kit according to the Affymetrix user manual: 
GeneChip® Whole Transcript (WT) Sense Target Labeling Assay GeneChip. Individual 
labeled samples were hybridized to the Mouse Gene 1.0 ST GeneChips® for 17 hours, 
then washed, stained and scanned with the standard protocol using Affymetrix GCOS 
(GeneChip® Operating System). GCOS was used to generate data (CEL files). The CEL 
file stores the results of the intensity calculations on the pixel values of the DAT file. 
This includes an intensity value, standard deviation of the intensity, the number of pixels 
used to calculate the intensity value, a flag to indicate an outlier as calculated by the 
algorithm and a user defined flag indicating the feature should be excluded from future 
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analysis (www.Affymetrix.com). Arrays were visually scanned for abnormalities or 
defects.  
 
CEL files were imported into Partek Genomics Suite (Partek, Inc., St. Louis, Mo). 
RMA signals were generated for the core probe sets using the RMA background 
correction, Quantile normalization and summarization by Median Polish. Summarized 
signals for each probe set were log2 transformed. These log transformed signals were 
used for Principal Components Analysis, hierarchical clustering and signal histograms to 
determine if there were any outlier arrays.  Untransformed RMA signals were used for 
fold change calculations. Data was analyzed using a 1-way Anova (analysis of variance) 
using log2-transformed signals with treatment as factor and all possible contrasts made. 
Fold changes were calculated using the untransformed RMA signals. Principal 
component analysis (PCA) and hierarchical clustering of the top 100 genes was done. 
 
B.6.c. Taqman Low Density Array. The ABI Taqman® microRNA Low Density 
Arrays for rodents (TLDA, Applied Biosystems, Foster City, CA) was used to analyze 
the expression of miRNAs between fasted and refed liver samples. The rodent TLDA 
consists of 2 arrays: TLDA A array and TLDA B array for 518 mouse-specific 
microRNAs. Each array/panel includes three endogenous controls including the 
mammalian U6 (MammU6) assay that is repeated four times on each card as a positive 
control as well as an assay unrelated to mammalian species, ath-miR159a, as negative 
control. Total RNA is first converted to cDNA using Megaplex
TM
 RT primer pools 
(Stem-loop RT primers for A and B arrays) and TaqMan® Universal PCR Master Mix is 
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simply combined with each reaction. One-hundred μl of this mix is then loaded onto each 
port of the TLDA array card. The TLDA plate was centrifuged with 9 up and down ramp 
rates at 1,200 rpm for 1 min and loaded into the 7900 HT Sequence Detection System 
using the 384-well TaqMan Low Density Array default thermal-cycling conditions. The 
ABI TaqMan SDS v2.3 software was utilized to obtain raw Ct values. To review results, 
the raw Ct data (SDS file format) were exported from the Plate Centric View into the ABI 
TaqMan RQ manager software. Automatic baseline and manual Ct were set to 0.2 for all 
samples. All the data was normalized to U87 expression. Delta Ct (ΔCt) values of 
miRNAs was calculated by subtracting the U87 Ct values from target miRNA Ct values. 
Delta delta Ct (ΔΔCt) values were obtained by taking a difference of the ΔCt of a miRNA 
between fasted and refed groups. ΔΔCt values were then converted into fold-change by 
using the formula 2
-ΔΔCt
. Anova analysis was performed to get differentially expressed 
miRNAs from 2
-ΔΔCt
 data. 
 
B.7. Western blotting. Primary hepatocytes were lysed in RIPA buffer (25 mM Tris-HCl 
pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS; Thermo 
Scientific, Rockford, IL) containing protease and phosphatase inhibitors (Roche, 
Indianapolis, IN). Cell extracts were centrifuged at 13,000 rpm, the fat layer carefully 
aspirated, and the supernatant was collected. Protein concentration was determined using 
the BCA kit from Pierce (Rockford, IL). Proteins (20-30 µg) were separated in 10% Tris-
HCl SDS PAGE Criterion gel (Bio-Rad, Hercules, CA) and transferred to 0.2-mm PVDF 
membrane (Bio-Rad, Hercules, CA). Antibodies to detect Rab11b, α-tubulin, LDLR, 
Timp3, FATP1, Cyc-40, IR- β, β-actin, Dync1li1 and Gck were used at the dilution 
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factors shown in Table 2. The secondary antibody horse radish peroxidase (HRP)-
conjugated anti-rabbit IgG (Cell Signaling, Boston, MA), was added and incubated at 
room temperature for 1 hour at a 1:3,000 - 1:5,000 dilution. Blots were developed with 
Pierce ECL kit (Thermo Scientific, Rockford, IL), and exposed to enhanced 
chemiluminescence (ECL) film (GE Healthcare, Piscataway, NJ). 
 
B.8. Northern blotting. miRNA-enriched (200 bp) RNA fractions were isolated from 
~100 mg of liver using mirVana RNA isolation kit according to the manufacturer’s 
instructions (Ambion, Austin, TX). Four μg of miRNA-enriched RNA was separated on 
15% TBE urea gels (Bio-Rad), transferred to Hybond-N membranes (GE Healthcare), 
and then UV-cross-linked using a Stratalinker 2400 (Stratagene). For miR-122 and 5s, 
DNA oligonucleotide probes were used. Probes (100 pmol) were labeled with DIG using 
a 2
nd
 generation DIG oligonucleotide tailing kit (Roche, Indianapolis, IN). Probes were 
hybridized to membranes at 25°C overnight in a hybridization oven after 2 hours of pre-
hybridization at 60°C. Three 2X SSC, 0.1% SDS washes were carried out for 10 min at 
room temperature followed by blocking and incubating with antibody against DIG. The 
signal was developed using CSPD (Roche, Indianapolis, IN) according to the 
manufacturer’s instructions. Probes used were as follows: miR-122: 
ACAAACACCATTGTCACACTCCA, 5s: TTAGCTTCCGAGATCA, miR-709: 
TCCTCCTGCCTCTGCCTCC and ATCCTCCTGCCTCTGCCTCCCC. In addition, to 
confirm the data, a 5’-DIG labeled miRCURY LNA Detection probe for miR-709 was 
used (TCCTCCTGCCTCTGCCTCC) (Exiqon, Woburn, MA, USA). For the miRCURY 
LNA probe, the protocol was followed as decribed
94
. 
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B.9. LDH assay. LDH measurements were performed on medium collected from 
Hepa1c1c cells transfected with miR-709 or Cel-239b, using the LDH Cytotoxicity 
Detection Kit (Clontech, CA, USA). At each timepoint, 100 μl of media from each well 
was collected and stored at -20°C. For analysis, the medium from each well was diluted 
1:4 in medium without FBS and glucose, and the company’s recommendations were 
followed. Absorbance was measured at 490 nm using a microplate reader. 
 
B.10. qPCR analysis 
B.10.a. qRT-PCR: qRT-PCR was performed for the following genes: Cluster of 
Differentiation 36 (Cd36), acyl-CoA oxidase 2 (Acox2), glucokinase (Gck), 
phosphofructokinase liver (Pfkl), member RAS oncogene family (Rab11b), 
carboxylesterase 1G (Ces1g), phosphatidylcholine transfer protein (Pctp) and TATA 
binding protein (Tbp), using the primer pairs shown in Table 1. qRT-PCR was performed 
using an ABI PRISM 7500 instrument (ABI, Foster City, CA) and the SYBR Green 
Qiagen One-Step reverse transcription-PCR kit (Qiagen, Valencia, CA), following the 
manufacturer's recommendations. A standard curve was generated with serial dilutions of 
an RNA sample from cells treated with the control miRNA (Cel-239b) (200 ng to 1.6 ng). 
Quantification of mRNA was measured by analyzing 50 ng of RNA, in duplicate, in a 50-
µl reaction volume and using 0.5 mM of each primer. Ct values were compared to those 
of the standard curve. The Tbp gene was used as loading control. Fold-changes are 
expressed relative to Cel-239b transfected cells.  
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B.10.b. TaqMan assay to quantify mature miRNAs: To quantify the level of mature 
miR-709, cDNA was generated from 10 ng of total RNA sample using the TaqMan 
miRNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA). Quantitative 
PCR was performed with TaqMan miRNA Assays (Applied Biosystems) specific for 
miR-709 (P/N 001644). As endogenous control, sno-202 was used (TaqMan miRNA 
Assay P/N 001232). 
 
B.11. Statistical analysis. All experimental conditions were done at least in duplicate 
and repeated in at least two separate hepatocyte isolations. Data are presented as the 
arithmetic mean ± standard deviation. Statistical differences were calculated using the 
unpaired two-tailed Student’s t-test. A p-value of less than 0.05 was considered 
statistically significant. 
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RESULTS 
 
A. Hepatic murine miRNA expression 
The importance of miRNAs regulating liver function was demonstrated recently 
in mice lacking Dicer in this tissue
95,96
. The hepatocytes in the knock-out mice displayed 
prominent steatosis and depleted glycogen stores
95,96
, and these mice were severely 
hypoglycemic after a short period of fasting. Recent work has also implicated miRNAs in 
other processes, including hepatic insulin sensitivity
50
. Given that miRNA expression 
profiles are tissue-specific and can be altered by developmental stage, cell cycle, or 
metabolic processes, the role of miRNA in liver needs to be established under specific 
conditions that are relevant to its function.  
 
A.1. Identification of miRNAs expressed in livers of normal and db/db mice 
To identify miRNAs dysregulated in livers of an animal model of type 2 diabetes 
relative to normal mice, the small RNA fraction of four C57BLKS/J and four db/db mice 
fed ad libitum, were obtained. Expression of 617 murine miRNAs was tested using chip 
miRNA microarrays (LC Sciences, Houston, TX). Of all the miRNAs expressed in the 
liver, miR-122 was the most abundant (Table 3). As described in the Introduction, miR-
122 has been well characterized and shown to be involved in various cellular processes 
such as fatty acid metabolism, amongst others
52,56
. Of all the differentially expressed 
miRNA (total of 22), those with a p-value < 0.01 were selected. These included miRNA-
709, miR-574-5p and miR-676, which were found significantly upregulated, and miR-
805 and miR-23a, which were significantly downregulated in db/db livers (Figure 11). A 
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published study showed that hepatic miR-709 expression increased 7.6-fold with ageing 
in mice
97
, suggesting a connection with metabolism. In addition, its abundance relative to 
other miRNAs made it particularly attractive to study, given the existing evidence that 
only the most abundant miRNAs suppress their targets, and that about 60% of the 
miRNAs are not active
98
. Predicted targets across multiple databases such as miRDB, 
TargetScan, and miRBase indicated a possible role in regulating genes important for cell 
adhesion/extracellular matrix (actin binding proteins, myosin proteins). Thus, we chose to 
further characterize the function of miR-709, based on its high abundance and potential 
role in controlling metabolic processes. 
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Figure 11. Hierarchical clustering analysis of miRNAs with p-value < 0.01. The 
clustering was done using a hierarchical method and was performed with average linkage 
and Euclidean distance metric. Red indicates higher expression and green indicates lower 
expression. 
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Table 3. miRNAs expressed in liver of normal C57BLKS/J mice. 
miRNA Mean miRNA signal S.D. 
mmu-miR-122 50,406 15,046 
mmu-miR-709 14,482 2,168 
mmu-let-7a 6,797 1,504 
mmu-let-7f 6,096 1,436 
mmu-let-7c 6,086 811 
mmu-let-7d 4,780 623 
mmu-let-7b 4,103 369 
mmu-miR-466f-3p 2,614 742 
mmu-miR-26a 2,346 288 
mmu-miR-467b* 1,842 499 
mmu-let-7g 1,520 351 
mmu-miR-192 1,463 227 
mmu-miR-689 1,159 617 
mmu-miR-23b 838 242 
mmu-miR-466i 782 240 
mmu-miR-720 778 455 
mmu-miR-467f 774 253 
mmu-miR-467a* 718 242 
mmu-miR-466g 554 154 
mmu-miR-574-5p 487 72 
mmu-miR-669f 463 161 
mmu-miR-191 456 170 
mmu-miR-483 451 91 
mmu-miR-705 378 132 
mmu-let-7i 370 107 
mmu-miR-690 369 48 
mmu-let-7e 369 169 
mmu-miR-21 355 355 
mmu-miR-805 352 131 
mmu-miR-24 350 125 
mmu-miR-1895 343 66 
mmu-miR-22 308 30 
mmu-miR-762 301 107 
mmu-miR-126-3p 293 120 
mmu-miR-26b 283 245 
mmu-miR-1224 262 72 
mmu-miR-23a 258 52 
mmu-miR-16 235 74 
mmu-miR-125b-5p 231 80 
mmu-miR-103 222 57 
mmu-miR-1187 210 39 
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mmu-miR-194 209 47 
mmu-miR-455 205 66 
mmu-miR-107 197 45 
mmu-miR-320 196 66 
mmu-miR-29a 190 119 
mmu-miR-574-3p 190 46 
mmu-miR-214 175 74 
mmu-miR-145 164 64 
mmu-miR-31 157 59 
mmu-miR-30c 155 49 
mmu-miR-378 153 34 
mmu-miR-1196 144 65 
mmu-miR-27b 140 46 
mmu-miR-151-5p 139 50 
mmu-miR-30d 117 16 
mmu-miR-92a 110 29 
mmu-miR-423-5p 108 32 
mmu-miR-361 105 34 
mmu-miR-1892 91 35 
mmu-miR-185 90 27 
mmu-miR-568 84 47 
mmu-miR-143 83 22 
mmu-miR-1897-5p 80 18 
mmu-miR-148a 69 71 
mmu-miR-681 68 63 
mmu-miR-669c 64 36 
mmu-miR-489 64 64 
mmu-miR-222 64 19 
mmu-miR-25 58 10 
mmu-miR-15b 57 28 
mmu-miR-30a 56 13 
mmu-miR-181a 52 9 
mmu-miR-188-5p 49 9 
mmu-miR-140* 49 22 
mmu-miR-27a 42 13 
mmu-miR-485* 42 7 
mmu-miR-221 40 13 
mmu-miR-680 39 30 
mmu-miR-92b 37 4 
mmu-miR-290-5p 37 23 
mmu-miR-30b 36 17 
mmu-miR-369-5p 35 53 
mmu-miR-101b 34 12 
mmu-miR-146a 33 16 
mmu-miR-199a-3p 33 4 
mmu-miR-20a 33 8 
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mmu-miR-99b 32 12 
mmu-miR-674 32 11 
mmu-miR-193 32 11 
 
A.2 Differential expression of hepatic miRNAs in the fasted and refed state 
 The transition from fasting to the refed state requires significant changes in 
hepatic mRNA profiles
99,100
. Most of the genes are implicated in lipid metabolism, 
cholesterol synthesis, gluconeogenesis and ketogenesis
99,100
, as expected from the 
established role of the liver at regulating these pathways in response to changes in levels 
of glucose and insulin. MicroRNAs are largely transcribed by RNA polymerase II and 
therefore, can be transcriptionally regulated like protein-encoding genes to change levels 
of genes needed for the metabolic switch between the fed and fasted periods. To 
determine whether miR-709 levels are influenced by nutritional/hormonal status, and to 
gain an insight on other miRNAs that could be regulated in such manner, we generated 
miRNA profiles in mice under fasted or refed conditions.  
 
Total RNA from 14-week old, male C57BL/6J mice (5 mice per group) was used 
in the study. Mice under fed conditions had free access to food throughout the study. 
Mice were fasted for 16 hours (fasted group) or fasted for 16 hours and refed for 5 hours 
(refed group) (Table 4). TaqMan Low Density Array (TLDA) cards A and B for rodents 
were used to analyze miRNA expression in four animals from the fasted versus the refed 
group. These two groups were used because we anticipated that if miRNA play a role at 
regulating metabolic genes, the largest differences in miRNA expression would occur 
between the fasted and refed periods, when genes involved in fatty acid oxidation, 
ketogenesis and gluconeogenesis need to be shutdown, while genes involved in 
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glycolysis and lipogenesis need to be upregulated. The A and B array cards together can 
detect 518 miRNAs specific to rodents. We have identified 39 miRNAs from the ‘A’ card 
and 22 miRNAs from the ‘B’ card that are differently expressed under fasting/refed 
conditions, with a fold-level of expression ranging from 1.5 to 32.4 (Table 5). It was 
striking to note that all miRNAs exept one (mmu-miR-21*) were downregulated under 
refed relative to fasting conditions, suggesting that miRNA control metabolic pathways 
mostly by inhibiting expression of gene targets during fasting conditions.  
 
Table 4. Blood glucose and body weight. 
 Fed Fasted Refed 
Glucose (mg/dl) 140.8±19.1 71.0±9.1 148.0±11.0  
Body weight (g) 29.0±2.4 26.4±1.1 28.2±2.2 
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 Table 5. miRNAs differentially expressed between fasted and refed 
groups. 
‘A’ Array 
miRNA Fold Change 
(Fasted/Refed) 
p-value 
mmu-miR-455 27.05 0.022 
mmu-miR-214 3.88 0.025 
mmu-miR-23b 2.93 0.013 
mmu-miR-676 2.90 0.023 
snoRNA202 2.87 0.018 
mmu-miR-25 2.86 0.005 
mmu-miR-99a 2.82 0.012 
mmu-miR-425 2.79 0.013 
mmu-miR-652 2.69 0.002 
mmu-miR-221 2.67 0.004 
mmu-miR-340-3p 2.58 0.019 
mmu-let-7g 2.50 0.017 
mmu-miR-181a 2.47 0.035 
mmu-miR-335-5p 2.33 0.021 
mmu-miR-145 2.17 0.026 
mmu-miR-125b-5p 2.17 0.006 
mmu-miR-532-5p 2.16 0.009 
mmu-miR-30c 2.12 0.017 
mmu-miR-199a-3p 2.03 0.000 
mmu-miR-381 1.98 0.020 
mmu-miR-590-5p 1.95 0.045 
mmu-let-7d 1.93 0.042 
mmu-miR-328 1.89 0.023 
mmu-miR-27a 1.86 0.033 
mmu-let-7b 1.85 0.003 
mmu-miR-146b 1.83 0.027 
mmu-miR-93 1.82 0.017 
mmu-let-7i 1.82 0.022 
mmu-miR-18a 1.80 0.047 
mmu-miR-152 1.80 0.022 
mmu-miR-365 1.74 0.031 
mmu-miR-26a 1.73 0.004 
mmu-miR-143 1.73 0.023 
mmu-let-7c 1.72 0.033 
mmu-miR-30b 1.72 0.028 
mmu-miR-195 1.68 0.039 
mmu-miR-122 1.54 0.021 
mmu-miR-148a 1.53 0.019 
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mmu-miR-103 1.52 0.008 
‘B’ Array 
miRNA Fold Change 
(Fasted/Refed) 
p-value 
mmu-miR-29b* 32.42 0.008 
mmu-miR-744* 15.79 0.003 
mmu-miR-28* 5.11 0.016 
mmu-miR-15b* 4.80 0.010 
mmu-miR-674* 4.11 0.040 
mmu-let-7a* 3.87 0.022 
mmu-miR-760 3.65 0.033 
mmu-miR-29c* 3.38 0.025 
mmu-miR-22* 2.79 0.006 
mmu-miR-214* 2.75 0.030 
mmu-miR-872* 2.56 0.020 
mmu-miR-193* 2.49 0.009 
mmu-miR-720 2.48 0.025 
mmu-miR-22* 2.34 0.015 
mmu-miR-22 1.98 0.026 
mmu-miR-706 1.92 0.045 
mmu-miR-31* 1.88 0.023 
mmu-miR-22 1.67 0.024 
mmu-miR-30a* 1.64 0.034 
mmu-miR-378 1.54 0.032 
mmu-miR-378 1.52 0.027 
mmu-miR-21* -29.52 0.025 
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The predicted targets of the 10 genes with >3-fold decrease/increase were 
identified using the DIANA-microT-CDS v5.0 database. This was followed by analysis 
using DIANA-miRPath v2.0 to perform hierarchical clustering of miRNAs and to 
identify pathways based on their interaction levels (Table 6). Several of these pathways 
were relevant to metabolic functions, including the PI3K-Akt and mTOR signaling 
pathways. By the time this thesis project started, the role of these miRNAs was unknown. 
Nevertheless, a recent literature search (at the end of this thesis project) on these miRNAs 
has shown that several of them have roles in hepatocellular carcinoma (miR-22
101-103
, 
miR-378
104
, miR-214
105
, miR-99a
106
, miR-195
107
, miR-27a
108
, miR-199a-3p
109
, let-7g
110
, 
let-7c
111
, miR-122
112
, miR-181a
113
, miR-145
114
, miR-148a
115
, miR-221
116
, miR-125b-
5p
117
, miR-590-5p
118
, miR-18a
119
, miR-93
120
, miR-25
121
), liver regeneration (miR-
23b
122,123
), liver cirrhosis (miR-652
124
, miR-181a
113
), liver fibrosis (miR-199a-3p
125
) and 
insulin sensitivity (miR-103
50
, miR-99a
126
, miR-145
127
, miR-143
128
).  
 
The results of the TaqMan Low Density Array showed that miR-709 was a highly 
expressed miRNA, confirming the microarray chip results (Table 3 and data not shown). 
However, the data indicated that miR-709 expression does not change significantly 
between the fasted to refed state. Thus, it is unlikely that this miRNA is needed to 
regulate pathways in response to insulin and/or metabolites that are generated during 
fasting or refeeding. Nevertheless, given that it was significantly upregulated in db/db 
animals, we questioned how miR-709 might contribute to the pathophysiology of type 2 
diabetes. Analysis of predicted targets using the databases miRanda and miRWalk, 
suggested a potential role on cell proliferation. Hepatic steatosis is a hallmark of type 2 
diabetes, and is associated with inflammatory processes and increased apoptosis, which 
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leads to cell repair and regeneration. Thus, we hypothesized that miR-709 would play a 
role in this response and proceeded with identifying its targets. 
 
Table 6. Predicted pathway regulation by miRNAs. 
Pathway/gene cluster miRNA 
PI3K-Akt signaling pathway let-7b, miR-199a, miR-25 
Focal adhesion miR-25, miR-199a 
Transcriptional misregulation in cancer let-7b, miR-199a 
Renin-Angiotensin system miR-26a, miR-193 
ECM-receptor interaction let-7b, miR-25 
Protein processing in endoplasmic reticulum miR-26a, miR-125b 
Pathways in cancer miR-103, miR-532 
Protein digestion and absorption let-7b, miR-26a 
Hypertrophic cardiomyopathy (HCM) miR-25, miR-26a 
mTOR signaling pathway miR-26a 
ErbB signaling pathway miR-199a 
Hedgehog signaling pathway miR-103 
N-Glycan Biosynthesis miR-26a 
Ubiquitin mediated proteolysis miR-125b 
Mucin type O-Glycan biosynthesis miR-125b 
Arrhythmogenic right ventricular cardiomyopathy miR-25 
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B. Targets of miR-709 in murine liver  
B.1. miR-709-3p is the mature strand of miRNA-709 
To determine which strand of the miRNA is loaded into the RNA-induced 
Silencing Complex (RISC), and therefore available for knockdown of its target genes, 
luciferase reporter constructs were generated containing the sequence complementary to 
the 5’ or 3’ strand of miR-709 (Figure 9). Primary hepatocytes were transfected with 
these plasmids and miR-709 mimic or control miRNA (Cel-239b). A 22.4-fold 
downregulation was seen specifically for the miR-709-3p construct, compared to control 
constructs (Figure 12). No effect was seen in cells transfected with miRNA-805, 
confirming the specificity of the binding. The plasmid specific for the miR-709-3p strand 
was also significantly downregulated in the Hepa1c1c cell line (Figure 13).  
 
Furthermore, primary hepatocytes transfected with a tough decoy (TuD) 
containing 8 copies of the sequence complementary to the 3’ strand showed a significant 
downregulation of luciferase expression relative to cells transfected with a plasmid 
without the sites (psiCHECK
TM
-2), indicating that the 3p is used as the guide strand for 
the endogenous miR-709 (Figure 14). Altogether, these data indicate that the 5p strand is 
not used by RISC and confirms that the 3p is used as the guide strand of miR-709 in 
murine liver. 
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Figure 12. miR-709 strand selection in primary hepatocytes. Primary hepatocytes 
were plated on 6-well plates at 4x10
5
 cells/well and transfected with 34 nM miR-709, 
miR-805 or Cel-239b, and 1.5 µg of plasmid p.miR-709-5p or p.miR-709-3p. Dual-
luciferase assays were performed on extracts prepared 24 hours later. Renilla luciferase 
activity was normalized to firefly luciferase expressed from the same plasmid. Cel-239b 
and miR-805 serve as negative control miRNAs. The results are representative of two 
independent experiments. Error bars represent the standard deviation. 
 
* 
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Figure 13. miR-709 strand selection in the Hepa1c1c7 cell line. Hepa1c1c7 cells were 
plated on 6-well plates at 1x10
5
 cells/well and transfected with miR-709, miR-805 or Cel-
239b, as described in Figure 12. Dual-luciferase assays were performed on extracts 
prepared 24 hours later. Renilla luciferase activity was normalized to firefly luciferase 
expressed from the same plasmid. Cel-239b and miR-805 serve as negative control 
miRNAs. The results are representative of two independent experiments. Error bars 
represent the standard deviation. 
 
61 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Strand selection of endogenous miR-709 in primary hepatocytes. Tough 
decoys were generated by cloning 8 copies of the sequence complementary to the 3p 
strand of miR-709 or the 5p strand of miR-122.  Primary hepatocytes were plated on 6-
well plates at 4x10
5
 cells/well and transfected with 2 μg of TuD122, TuD709 or 
psiCHECK
TM
-2 (psiCK2) using Metafectene-Pro at 1:4 ratio. Dual-luciferase assays were 
performed on extracts prepared 40 hours later. Renilla luciferase activity was normalized 
to firefly luciferase expressed from the same plasmid. TuD122 was used as positive 
control, and psiCHECK
TM
-2 as reference for luciferase expression. n = 3, with error bars 
representing the standard deviation. *p < 0.05 TuD vs psiCHECK
TM
-2. The same data 
was obtained from two independent experiments. 
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B.2. miR-709-regulated transcriptome 
To identify gene targets of miR-709, mouse primary hepatocytes were transfected 
with miR-709 mimic or Cel-239b. Increased levels of miR-709 (3.8-fold) were confirmed 
by TaqMan miRNA assay in cells harvested 24 hours post-transfection (Figure 15). Gene 
expression profiles were then generated using murine-specific Affymetrix mRNA 
microarrays (n = 3-4). The short time frame (24 hours) allowed identifying direct targets 
of miR-709, reducing the possibility of detecting changes in mRNA levels due to 
secondary effects. 
 
Close to 570 genes were seen downregulated in miR-709-treated cells, compared 
to Cel-239b. Hierarchical cluster of the top 100 genes was done by ANOVA, arrays 
Euclidean distance, genes Pearson’s dissimilarity and average linkage (Figure 16). Of the 
28,850 genes on the microarray, 36 genes were significantly downregulated >2-fold and 
10 genes were downregulated >3-fold in the miR-709 group compared to control Cel-
239b-treated cells (Table 7; p-value <0.01). The list of downregulated genes was further 
analyzed using bioinformatic analysis resource DAVID (Database for Annotation, 
Visualization and Integrated Discovery)
129,130
 and GENEGO Databases using pathway 
analysis and metabolic maps. The results of this analysis suggested a role for this miRNA 
at controlling cellular processes involved in lipid synthesis and transport (Ces1g, Pctp, 
Daglb), cytoskeleton organization (Rab11b, Dync1li1, Acta2, M6prbp1, Myo1d) and cell 
adhesion (Timp3, Nid1, Thbs1, Krt19). 
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Figure 15. miR-709 quantification in primary hepatocytes transfected with mimic. 
Primary hepatocytes were plated on 6-well plates at 5x10
5
 cells/well and transfected with 
34 nM of miR-709 or Cel-239b using Metafectene-Pro at 1:6 ratio. Cells were harvested 
24 hours later and mature miR-709 was quantified by TaqMan assay. A 3.8-fold increase 
was observed relative to Cel-239b-treated cells. snoRNA-202 was used as normalizer. 
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Figure 16. Hierarchical cluster of top 100 genes. Analysis was done by ANOVA arrays 
Euclidean distance, genes Pearson’s dissimilarity, and average linkage. The top 
dendogram separates genes by their expression pattern. Blue indicates lower and red 
indicates higher signals. The dendogram on the left separates the two treatment groups – 
miR-709 and Cel-239b. 
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Table 7. Genes significantly downregulated >2-fold in miR-709-treated 
compared to Cel-239-treated primary hepatocytes. 
Gene  
symbol 
Gene name Fold 
change 
p-value 
Tspan31 Tetraspanin 31 -5.27 1.8E-06 
Rab11b Ras-related protein  -4.18 6.5E-06 
Cyp20a1 
Cytochrome P450, Family 20, Subfamily 
A, Polypeptide 1 
-3.76 1.2E-07 
Dync1li1 
dynein, cytoplasmic 1, light intermediate 
chain 1  
-3.40 2.3E-07 
Bpnt1 3'(2'), 5'-bisphosphate nucleotidase 1 -3.28 9.3E-09 
Mmachc 
methylmalonic aciduria (cobalamin 
deficiency) cblC type, with 
homocystinuria 
-3.27 1.5E-05 
Ces1 carboxylesterase 1 -3.22 1.7E-06 
Timp3 Tissue Inhibitor Of Metalloproteinases 3 -3.20 4.6E-05 
Pctp phosphatidylcholine transfer protein -3.19 6.2E-07 
Nid1 nidogen 1 -3.03 2.7E-06 
Slc35e1 solute carrier family 35, member E1 -2.95 3.7E-09 
Mare 
alpha globin regulatory element 
containing gene 
-2.75 7.0E-08 
D13Wsu177e 
DNA segment, Chr 13, Wayne State 
University 177, expre 
-2.71 1.7E-08 
Thbs1 thrombospondin 1 -2.67 2.1E-06 
Lrrc58 leucine rich repeat containing 58 -2.53 6.2E-07 
Acta2 actin, alpha 2, smooth muscle, aorta -2.52 1.4E-05 
M6prbp1 
mannose-6-phosphate receptor binding 
protein 1 
-2.50 1.7E-06 
Atrn attractin -2.46 4.7E-06 
Mpzl2 myelin protein zero-like 2 -2.41 4.1E-06 
Tagln transgelin -2.36 6.6E-06 
Cnn1 calponin 1 -2.36 4.0E-05 
Krt19 keratin 19 -2.35 2.9E-03 
Myo1d myosin ID -2.31 1.5E-07 
Cyb5d2 cytochrome b5 domain containing 2 -2.29 1.1E-06 
Actc1 actin, alpha, cardiac muscle 1 -2.29 1.3E-05 
Pfas 
phosphoribosylformylglycinamidine 
synthase  
-2.27 1.1E-08 
Ggcx gamma-glutamyl carboxylase -2.20 7.5E-05 
Ccnyl1 cyclin Y-like 1 -2.17 1.0E-05 
Amt aminomethyltransferase -2.16 2.0E-04 
BC057893 cDNA sequence BC057893 -2.12 3.3E-06 
Gpr155 G protein-coupled receptor 155 -2.05 1.7E-04 
Daglb diacylglycerol lipase, beta -2.05 2.7E-06 
Sema6a sema domain, transmembrane domain -2.04 9.4E-05 
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(TM), and cytoplasmic 
Fnip2 folliculin interacting protein 2 -2.01 3.9E-04 
Slc7a1 
solute carrier family 7 (cationic amino 
acid transporter 
-2.01 1.6E-06 
Mobkl2a 
MOB1, Mps One Binder kinase activator-
like 2A (yeast) 
-2.00 2.3E-05 
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To validate the microarray results, CD36, Acox2, Gck, Pfkl, Rab11b, Ces1g and 
Pctp were analyzed by quantitative real time PCR. Identical trends to those observed in 
the microarray analysis were observed (Figure 17). Interestingly, Rab11b, Pctp and 
Ces1g showed more than 5-fold downregulation upon validation, which was greater than 
what was observed in the microarray analysis. The decrease in gene expression was 
maintained for at least 4 days (Figure 18). Changes were confirmed at protein level for 
several genes, including Rab11b, Dync1li1 and Timp3 (Figure 19). The low-density 
lipoprotein receptor (Ldlr) was 1.2-fold downregulated in the microarray (p=0.004), but 
remained unaltered at protein level, suggesting that small changes in mRNA levels had 
no impact at protein level (Figure 19). Remarkably, levels of Rab11b, Dync1li1 and 
Timp3 were lower in primary hepatocytes within 48 hours of transfection with miR-709 
(Figure 19). miR-709 induced a 90% decrease in Rab11b protein levels and a 70% 
decrease in Dync1li1 protein expression. Consistent with these data, Rab11b protein 
levels were also significantly reduced in Hepa1c1c cells transfected with miR-709 
mimics (Figure 20). 
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Figure 17. Real time RT-PCR analysis of miR-709 targets. Cluster of Differentiation 
36 (CD36), Acyl-CoA oxidase 2 (Acox2), Ras-related protein (Rab11b), 
phosphofructokinase, liver (Pfkl), phosphatidylcholine transfer protein (Pctp), 
glucokinase (Gck) and carboxylesterase 1g (Ces1g) were analyzed by qPCR. Mouse 
primary hepatocytes were plated on 6-well plates at 1x10
6
 cells/well and transfected with 
34 nM miR-709 or Cel-239b using Metafectene-Pro at 1:6 ratio. Cells were harvested 24 
hours later (n = 4; error bars represent the standard deviation). TATA Binding protein 
(Tbp) was used as normalizer gene. *p<0.05 relative to Cel-239b-treated. The fold-
change for each gene relative to Cel-239b-treated is plotted. 
* * 
* * 
* 
* * * 
* 
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Figure 18. Prolonged downregulation of miR-709 targets over time. Real time RT-
PCR analysis of Ras-related protein (Rab11b), phosphatidylcholine transfer protein 
(Pctp) and tissue inhibitor of metalloproteinases 3 (Timp3). Mouse primary hepatocytes 
were plated on 6-well plates at 4x10
5
 cells/well and transfected with 34 nM miR-709 or 
Cel-239b using Metafectene-Pro at 1:6 ratio. Cells were harvested at 24, 48, 72 and 96 
hours post-transfection (error bars represent standard deviation). TATA binding protein 
(Tbp) was used as normalizer gene. The mRNA expression for each gene is plotted. 
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Figure 19. miR-709 on Rab11b, Timp3 and Dync1li1 protein levels. (A) Primary 
hepatocytes were plated on 6-well plates at 4x10
5
 cells/well and transfected with miR-
709 or Cel-239b using Metafectene Pro. Media was replaced 24 hours post-transfection 
and cells were harvested 48 hours or 96 hours later. Rab11b, Dync1li1, Timp3, Ldlr, IR-
ß, Fatp1 and Gck protein expression was analyzed by Western blot. Cyclophillin-40 and 
ß-actin are normalizers. Data are representative of at least 3 independent experiments 
with at least 4 replicates for each group. (B) Bands on blot were quantified by 
densitometry and results were normalized to -actin or cyclophilin-40. *p<0.01 relative 
to Cel-239b, #p<0.06 relative to Cel-239b. 
 
 
 
(A) (B) (
A
) 
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Figure 20. miR-709 decreases Rab11b in Hepa1c1c cells. Hepa1c1c cells were plated 
on 6-well plates at 4x10
5
 cells/well and transfected with 34 nM of miR-709 or Cel-239b. 
Media was replaced 24 hours post-transfection and cells were harvested 72 hours later. 
Rab11b protein expression was analyzed by Western blot. ß-actin acts as normalizer. 
Data are representative of 3 replicates for each group. (B) Bands on blot were quantified 
by densitometry and results were normalized to -actin. *p<0.01 relative to Cel-239b. 
(A) 
(
B) 
(B) 
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B.3. Ces1g, Rab11b and Pctp are direct targets of miR-709 
miRNAs act on their target genes mostly by binding to the 3’ untranslated region 
(UTR) of their mRNAs. We have shown that miR-709 downregulates Rab11b, Pctp, and 
Ces1g. To confirm that these are direct gene targets, we used the miRanda database to 
identify predicted binding sites for miR-709 on the 3’ UTR of these genes. Rab11b, Pctp 
and Ces1g had 3, 2 and 1 predicted binding sites, respectively. Using PCR, we amplified 
the 3’ UTR of Rab11b, Ces1g and Pctp containing at least one of the miR-709 binding 
sites (Figure 21), and cloned them in plasmid psiCHECK
TM
-2 (Figure 9). As negative 
control for each gene, a fragment of the 3’ UTR without miR-709 binding sites was 
amplified and cloned in psiCHECK
TM
-2. Primary hepatocytes were transfected with these 
constructs together with miR-709 mimic or Cel-239b, and harvested 24 hours later. 
Lower levels of Renilla luciferase were observed in the constructs containing binding 
sites for miR-709 (p.Rab11b, p.Pctp and p.Ces1g), compared to constructs that had a 
fragment of the 3’ UTR without the miR-709 target sequence (p.NC-Rab11b, p.NC-Pctp 
and p.NC-Ces1g) (Figure 22). These data confirm that Rab11b, Pctp and Ces1g are direct 
targets of miR-709. 
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Figure 21. miR-709 putative binding sites in the 3’ UTR of Rab11b, Ces1g and Pctp. 
The primers (shown in green) were designed such that they flanked the putative miR-709 
binding site (shown in red) for each gene. The 3’ UTR fragment used as negative control 
(NC) was amplified using primers that bind outside of the miR-709 binding sites (shown 
in blue). The size of the 3’ UTR amplified by PCR for Rab11b, NC-Rab11b, Ces1g, NC-
Ces1g, PCTP and NC-PCTP are 712, 261, 253, 236, 365 and 237 bp respectively.  
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Figure 22. Rab11b, Pctp and Ces1g are direct targets of miR-709. Primary 
hepatocytes were plated on 6-well plates at 4x10
5
 cells/well and transfected with 34 nM 
miR-709 or Cel-239b, and 1.5 µg of plasmids containing the 3’ UTR of Rab11b, Pctp and 
Ces1g. Twenty-four hours later, dual-luciferase assays were performed. Renilla luciferase 
activity was normalized to firefly luciferase expressed from the same plasmid (n=3). 
Error bars represent the standard deviation. The experiment was performed in two 
independent experiments with identical results. p-values (*p < 0.01) are relative to cells 
treated with the same plasmid using Cel-239b miRNA. p.miR-709, plasmid containing 
the sequence perfectly complementary to miR-709-3p strand; p.Pctp, p.Ces1g and 
p.Rab11b, plasmids containing a fragment of the 3’ UTR with miR-709 binding sites; 
p.NC-Pctp, p.NC-Ces1g and p.NC-Rab11b, plasmids with a fragment of the 3’ UTR 
without miR-709 binding sites. 
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B.4. Database gene predictions 
Multiple databases are available to identify predicted targets of miRNA. To 
determine the accuracy of these predictions, we compared the list of the genes 
downregulated at least 2-fold, with target predictions from seven databases, including 
miRanda
74
, miRDB
79,80
, miRWalk
81
, TargetScan
82
, DIANAmT
83,84
, miRBase
85-91
, 
PICTAR5
92
 and RNA22
93
 (Table 8). The predictions were based on presence of the miR-
709 putative binding site in the 3’ UTR of the mRNAs. This analysis revealed that 
miRanda, miRWalk, DIANAmT and PICTAR5 are the best database predictors of 
miRNA targets, with 60-70% of gene predictions, while miRDB, TargetScan and RNA22 
predicted less than 22% of the genes that were found downregulated. Only one gene was 
predicted by all databases (Myo1d) (Table 8) and 22% of genes were not predicted by 
any of them.  
 
miR-709 is not a conserved miRNA, and the human ortholog is hsa-miR-1827, 
which shares the same seed sequence (UGAGGCAGUAGAUUGAAU). Analysis of 
predicted hsa-miR-1827 targets using the miRWalk database, indicates that similar genes 
and pathways are regulated by both miRNA (Table 9). Overall, approximately 61% of 
miR-709 target genes are also predicted targets of miR-1827. Given that the miRWalk 
database only predicted 69% of the actual miR-709 targets, it is likely that the number of 
commonly targeted genes is higher. 
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Table 8. Predicted versus observed miR-709 target genes. 
    Database 
Gene FL mR mD mW TS DT PT5 R22 
Tspan31 -5.3 * * *  * *  
Rab11b -4.2 * * *  * *  
Cyp20a1 -3.8        
Dync1li1 -3.4 *  *  * * * 
Bpnt1 -3.3 *  *  * *  
Mmachc -3.3        
Ces1 -3.2 *  *  * *  
Timp3 -3.2 *  * * * *  
Pctp -3.2 *  * * * *  
Nid1 -3.0     * *  
Slc35e1 -3.0 * * *  * *  
Mare -2.8 *  *  * * * 
D13Wsu177e -2.7 *  *  * *  
Thbs1 -2.7 * * *  * *  
Lrrc58 -2.5 *  *  * *  
Acta2 -2.5 *  * *   * 
M6prbp1 -2.5 *  *  * *  
Atrn -2.5 * * * * * *  
Mpzl2 -2.4 *  *  * *  
Tagln -2.4 * *  * * *  
Cnn1 -2.4      *  
Krt19 -2.4        
Myo1d -2.3 * * * * * * * 
Cyb5d2 -2.3        
Actc1 -2.3       * 
Pfas -2.3        
Ggcx -2.2 *  *  * * * 
Ccnyl1 -2.2        
Amt -2.2        
BC057893 -2.1 *  *  * *  
Gpr155 -2.1 *    *   
Daglb -2.1 *  *  * *  
Sema6a -2.1 *   *  *  
Fnip2 -2.0        
Slc7a1 -2.0 *  * * * *  
Mobkl2a -2.0 *  *  * *  
TOTAL PREDICTED: 
(%): 
 
25 
(69) 
7 
(20) 
22 
(61) 
8 
(20) 
24 
(67) 
25 
(69) 
6 
(17) 
TOTAL UNPREDICTED: 
(%): 
 
11 
(31) 
29 
(80) 
14 
(39) 
28 
(80) 
12 
(33) 
11 
(31) 
30 
(83) 
FL, fold-level; mR, miRanda; mD, miRDB; mW, miRWalk; TS, Targetscan; DT, 
DIANAmT; PT5, PICTAR5; R22, RNA22; * predicted. 
 
 
77 
 
 
Table 9. Overlap between mmu-miR-709 target genes and hsa-miR-1827 
predicted targets. 
miR-709 miR-1827 
Tspan31 TSPAN32 
Rab11b RAB11FIP5 
Cyp20a1 CYP19A1 
Dync1li1 DYNLL2 
Bpnt1 BPNT1 
Mmachc MMACHC 
Timp3 TIMP4 
Pctp STARD3 
Slc35e1 SLC35C1, SLC35E4 
Mare NPR3 
Thbs1 THBS1 
Lrrc58 LRRC58 
Tagln TAGLN 
Cnn1 CNN3 
Krt19 Many KRT proteins 
Myo1d Many MYO proteins 
Cyb5d2 CYB561D2 
Pfas PFAS 
Gpr155 Many GPR proteins 
Sema6a SEMA6A 
Fnip2 FNIP1 
Slc7a1 SLC7A60S 
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C. Biological role of miR-709 in liver  
C.1. miR-709 gene targets do not regulate hepatocyte polarity  
A coordinated role between Rab11 and Dync1li1 in membrane trafficking has 
been described in A431 cells, a human epidermal carcinoma cell line
131
. However, the 
role of these proteins in hepatic function is unknown. The Rab family of proteins is a 
group of small GTPases that regulate various facets of endosomal trafficking
16,132
. Rab 
proteins participate in vesicle formation, trafficking and fusion and are often associated 
with cytoskeletal motor proteins
133
. Rab11b is one of the widely studied members of the 
Rab11 family and is ubiquitously expressed
133
. It localizes to apical vesicles separated 
from the Rab11a compartment in MDCK and gastric parietal cells
132,134,135
. Rab11b plays 
a critical role in apical recycling of epithelial sodium channel (ENaC) in mpkCCD 
cells
133
 and has been shown to interact with its effector protein Rip11 in insulin granule 
exocytosis
136
. Cytoskeletal motor proteins are accountable for the trafficking of 
endocytosed material between the surface of the cell and intracellular compartments
137
. 
Dynein cytoplasmic light chain 1 (Dync1li1) is a component of the Dynein-1 complex, a 
minus-end-directed microtubule–based motor protein131,138-142. Rab11 along with its 
effector protein FIP3 acts together with Dync1li1 and guides membrane trafficking from 
peripheral sorting endosomes to the endosomal recycling compartment (ERC)
131
. Given 
that Rab11b and Dync1li1 were among the top downregulated genes, we hypothesized 
whether a role of miR-709 is to regulate hepatocyte polarization and trafficking.  
 
To study if miR-709 affected the capacity of primary hepatocytes to maintain 
polarity and form bile caniculi, a sandwich cell culture model was established to enable 
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adjacent hepatocytes to form bile canaliculi and mimic the 3D arrangement of the murine 
liver (Figure 4). Primary hepatocytes were cultured on collagen-I coated glass coverslip 
bottom 6-cm dishes, and the next day, cells were washed and overlaid with Matrigel
TM 
(see Methods: Primary hepatocyte isolation)
77
. Bile canaliculi were apparent 24 hours 
later and maintained for several days (Figure 23). Unlike primary hepatocytes cultured in 
a conventional monolayer, which lose hepatocyte-specific functions as the result of 
dedifferentiation, the sandwich model enables hepatocytes to form intact bile canaliculi 
closed by tight junctions, retaining their function for several weeks
12,143
. Cells cultured 
under these conditions secrete albumin, urea, transferring, fibrinogen, and bile acids
144
. 
Next, we tested the capacity of these bile canaliculi to transport sodium fluorescein, a 
substrate for Multidrug resistance-associated protein 2 (Mrp2), a protein found on the 
membrane of the bile canaliculi. Within 30 minutes, sodium fluorescein dissappeared 
from the cytoplasm of cells and became visible in the bile canaliculi (Figure 24). 
 
To study if the alterations in gene expression affected the capacity of the 
hepatocytes to maintain polarity and form bile canaliculi, primary hepatocytes were 
transfected with miR-709 or Cel-239b, 4 hours after plating. The next day, cells were 
covered with Matrigel
TM
 to allow contact between adjacent cells. miR-709 and Cel-239b 
transfected cells could form bile canaliculi between cells within 24 hours that were 
maintained for at least 4 days, without a noticeable difference between the two groups. 
Furthermore, uptake and transport of sodium fluorescein into the bile canaliculi was 
similar for both miR-709 and Cel-239b-treated hepatocytes (Figure 25). These data 
indicate that miR-709 does not influence the establishment and maintenance of 
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hepatocyte polarity, the formation of bile canaliculi, and the intracellular transport of 
Mrp2 substrates. Given that Rab11b was one of the highest downregulated genes, and its 
function in liver is unknown, we tested whether knocking it down with siRNA would 
lead to abnormal transport of sodium fluorescein. Similar results were obtained in 
sandwich cultures of primary hepatocytes transfected with a combination of two siRNAs 
against Rab11b (siRab11b-1 and siRab11b-2), or control siRNA (siNC) (Figure 26 and 
Figure 27). Therefore, we concluded that Rab11b was not essential for the ability of 
primary hepatocytes to be polarized nor did it alter the apical transport of an Mrp2 
substrate.  
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Figure 23. Formation of bile canaliculi between primary hepatocytes cultured in a 
sandwich configuration. Primary hepatocytes were plated on 35-mm glass bottom 
collagen-coated dishes at 6x10
5
 cells/well. The following day, Matrigel
TM
 was added on 
top of the cells. Images were acquired with a Nikon TE 2000 U inverted microscope 96 
hours post-addition of Matrigel
TM
. Images were acquired with a 20x or 40x Air EL WD 
Plan Fluor 0.60NA Differential interference contrast objective (Melville, NY) and a Sony 
DSCW170 16.1 MP digital camera. Arrows point at bile canaliculi. 
 
 
20x 
40x 
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Figure 24. Uptake and secretion of sodium fluorescein. Primary hepatocytes were 
plated on 35-mm glass bottom collagen-coated dishes at 6x10
5
 cells/well. Matrigel
TM
 was 
added to cells the following day. Cells were assayed for sodium fluorescein transport 96 
hours post Matrigel
TM
 overlay. Na-F, sodium fluorescein. 
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Figure 25. Sodium fluorescein transport in primary hepatocytes transfected with 
miR-709 or Cel-239b. Primary hepatocytes were plated on 35-mm glass bottom collagen 
coated dishes at 6x10
5
 cells/well and transfected with 34 nM miR-709 or Cel-239b. 
Matrigel
TM
 was added to cells the following day. Cells were assayed for sodium 
fluorescein transport 72 hours post-transfection.  
84 
 
 
 
Figure 26. Rab11b silencing in mouse primary hepatocytes. (A) Primary hepatocytes 
were plated on 6-well plates at 6x10
5
 cells/well and transfected with 30 nM of siRNAs to 
knockdown Rab11b (siRab11b-1, siRab11b-2) or negative control siRNA (siNC) or a 1:1 
complex of both siRab11b-1 and siRab11b-2. Media was replaced 24 hours post-
transfection and cells were harvested 24 hours later. Rab11b was quantified by Western 
blot. Tubulin was used as normalizer (n=3). (B) Densitometry analysis of Western blot; 
Rab11b expression was normalized to tubulin. * p-value <0.001.  
 
(B) 
(A) 
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Figure 27. Sodium fluorescein transport in primary hepatocytes treated with 
siRab11b. Primary hepatocytes were plated on 35-mm glass bottom collagen-coated 
dishes at 6x10
5
 cells/well and transfected with 30 nM of a combination of siRab11b-1 
and siRab11b-2 (1:1 ratio) or negative control siRNA (siNC). Matrigel
TM
 was added to 
cells the following day. Cells were assayed for sodium fluorescein transport 72 hours 
post-transfection. 
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C.2. Intracellular localization of miR-709 
Recently, miR-709 has been shown to regulate the processing of a miRNA cluster 
in the nucleus of fibroblast cells
145
. miR-709 binds to a miR-709 binding element in the 
primary transcript of miR-15a/16-1 and prevents further processing into precursor or pre-
miR-15a/16-1
145
. The same group reported that miR-709 was mostly localized in the 
nucleus
145
. In fibroblasts, apoptosis-inducing stimuli such as serum starvation, elicited 
miR-709 translocation to the cytoplasm, without altering the total levels of the miRNA in 
the cell
145
. This change in localization resulted in loss of inhibition of miR-15a/16-1 
processing and led to downregulation of a well-characterized miR-15a/16-1 target, B-cell 
lymphoma 2 (Bcl-2)
145
. Bcl-2 is an anti-apoptotic gene that prevents cell death by 
blocking activation of caspases, downstream activators of apoptosis
146
. The authors 
concluded that miR-709 was sensitive to apoptotic stimuli and it indirectly affected 
apoptosis through regulation of Bcl-2 levels
145
. 
 
To study the cellular localization of miR-709, primary hepatocytes were co-
transfected with a 3’-FAM-labeled miR-709 or Dy547-labeled miRIDIAN miRNA 
Mimic Transfection Control (Thermo Fisher, CO). This control miRNA is cytoplasmic, 
like the majority of mature miRNAs. Both, miR-709 and the control miRNA were found 
localized only in the cytoplasm of primary hepatocytes (Figure 28). To determine 
whether the intracellular localization of miR-709 depends on cell division, Hepa1c1c 
cells were co-transfected with the two miRNA. Similar to what was observed in primary 
hepatocytes, both miRNAs were located in the cytoplasm of Hepa1c1c cells (Figure 29). 
Next, we tested if serum and glucose starvation would have an impact on the cellular 
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distribution of miR-709. For this, Hepa1c1c cells transfected with 3’-FAM-labeled miR-
709 and Dy547-labeled miRIDIAN microRNA Mimic Transfection Control were 
subjected to serum and glucose starvation and observed 24 hours later. Both miRNAs 
were seen only in the cytoplasm, co-localizing in the same area (Figure 29). Single 
transfection of 3’-FAM-labeled miR-709 gave the same result, discarding the possibility 
that the control miRNA infuences the localization of miR-709 (Figure 30). Thus, in 
normal liver cells and in hepatoma cells, mature miR-709 is only localized in the 
cytoplasm of the cells. Also, cellular stress such as starvation did not result in change in 
localization of miR-709 in hepatoma cells. 
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Figure 28. Intracellular localization of miR-709 in primary hepatocytes. Primary 
hepatocytes were plated on 35-mm glass bottom collagen-coated dishes at 6x10
5
 
cells/well and co-transfected with 17 nM of 3’-FAM-labeled miR-709 and 17 nM of 
Dy547-labeled miRIDIAN microRNA Mimic Transfection Control. Next day, media was 
replaced and cells were imaged using confocal fluorescence microscopy. Nuclei were 
stained with Hoechst 33342. Scale bar, 15 μm.  
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Figure 29. Intracellular localization of miR-709 in Hepa1c1c cells. Hepa1c1c cells 
were plated on 35-mm glass bottom collagen coated dishes at 4x10
5
 cells/well and co-
transfected with 17 nM of 3’-FAM-labeled miR-709 and 17 nM of Dy547-labeled 
miRIDIAN microRNA Mimic Transfection Control. Next day, media was replaced with 
medium with/without glucose and FBS. Twenty-four hours later, cells were imaged using 
confocal fluorescence microscopy. Nuclei were stained with Hoechst 33342. Scale bar, 
15 μm. 
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Figure 30. Cytoplasmic miRNA localization in Hepa1c1c cells transfected with 
miRNA-709. Hepa1c1c cells were plated on 35-mm glass bottom collagen coated dishes 
at 4x10
5
 cells/well and transfected with 34 nM 3’-FAM-labeled miR-709. Next day, 
media was replaced with medium with/without glucose and FBS. Twenty-four hours 
later, cells were imaged using confocal fluorescence microscopy. Nuclei were stained 
with Hoechst 33342. Scale bar, 15 μm 
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C.3. Pre-miR-709 accumulates in liver 
To further gain an insight on the relative abundance of precursor and mature form 
of miR-709, levels were analyzed by Northern blot. Remarkably, in normal liver, the 
precursor miR-709 was present at high levels, while the mature form was scarce, contrary 
to what is typically seen for most miRNAs
147
, including miR-122 (Figure 31 and Figure 
32). This suggested the possibility that pre-miR-709 is the major form of miR-709, and 
only in the presence of appropriate signals, it is transported to the cytoplasm for Dicer 
processing and production of the mature form. Consistently with these data, when 
HEK293 and Hepa1c1c cells were transfected with plasmids expressing miR-709 primary 
transcript (p.pri-miR-709), there was no increase in levels of mature miR-709 (Figure 
33). This suggests that the majority of primary transcript expressed is not processed to 
mature miR-709. 
 
Given the nature of the gene targets of miR-709 (Tspan31, Rab11, Thbs1, Timp3, 
Tagln, Cnn1, Krt19), we questioned whether this miRNA might be needed in liver cells 
actively dividing. Thus, we tested the relative abundance of pre-miR-709 and mature 
miR-709 in a mouse model of hepatocellular carcinoma, and in a model of liver 
regeneration after partial hepatectomy
148
. Cell proliferation, mitosis and expression of 
cell cycle proteins in the model of partial hepatectomy peaks at 36 and 44 hrs
148
. Hence, 
these timepoints were used for this study. Remarkably, we found that the levels of mature 
miR-709 were significantly increased in liver tumor and regenerating livers (Figures 31 
and 34). Taqman real-time PCR was used to confirm the increase in levels of mature 
miR-709 (Figure 35).  
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Several lines of evidence suggest that the half-life of a miRNA can be regulated at 
the biosynthesis as well as decay level. Some miRNA are inherently unstable and have 
short half-lives
149
. In others, the stage of the cell cycle as well as the presence of growth 
factors, influences miRNA stability without affecting transcription of the primary 
transcript
150
. MiR-709 is localized in intron 8 of the Rfx1 gene, which encodes for a 
transcription factor with a function not well characterized in liver. Rfx1 inhibits c-Myc 
and Proliferating Cell Nuclear Antigen  (PCNA), both critical genes for cell 
proliferation
151-153
. To determine whether the increase of miR-709 is the result of 
increased expression of Rfx1, its mRNA was analyzed by qPCR. Levels of Rfx-1 were 
found 5.2-fold upregulated in tumor samples (Figure 35), indicating that the increased 
levels of mature miR-709 are likely the result of increased transcription of the host gene. 
These data link Rfx1 to liver cell proliferation. 
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Figure 31. Relative abundance of miR-709 in an animal model of hepatocellular 
carcinoma. Northern blot analysis using 4 μg of small RNA fraction. A DIG-labeled 
miR-709 LNA probe was used for detection of miR-709. LapMyc male (tumor and 
adjacent normal tissue; n=5), LapMyc female (n=2), FVB female and Myc male mouse 
liver RNA was used to probe for miR-709 by Northern blotting. The ribosomal RNA 5s 
was used as loading control. The LapMyc mice are bi-transgenic. c-Myc oncogene 
expression is conditionally regulated via Tet-Off system. The tetracycline-transactivator 
(tTA) protein is driven by the liver-specific promoter, Liver Activator Protein (LAP), and 
the c-Myc gene (in the Y chromosome) has a tetracycline response element. In the 
absence of doxycycline, tTA can bind to the response element and cause c-Myc 
expression in male mice. This causes the male mouse livers to develop spontaneous 
tumors. c-Myc expression was induced at 4 weeks of age and animals were sacrificed at 
14 weeks of age. LapMyc females are control mice that received doxycycline (and did 
94 
 
not express c-Myc). FVB are wild type female mice. Myc male mice are parents of 
LapMyc mice. LapMyc female, FVB and Myc mice are negative controls.  
 
 
 
 
Figure 32. Relative abundance of miR-122 in an animal model of hepatocellular 
carcinoma. Northern blot analysis using 4 μg of the small RNA fraction. An 
oligonucleotide probe was used for detection of miR-122. LapMyc male mouse liver 
(tumor and adjacent normal tissue; n=5) RNA was used to probe for miR-122. The 
ribosomal RNA 5s was used as loading control. For miR-122, the mature form is more 
abundant than the pre-miR-122 in normal liver. 
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Figure 33. Levels of mature miR-709 in HEK293 and Hepa1c1c cells upon 
transfection with plasmids expressing pri-miR-709 or pri-Cel-239b. HEK293 (A) or 
Hepa1c1c (B) cells were transfected with 2 μg of p.pri-miR-709 or p.pri-Cel-239b and 
harvested 24 later. Mature miR-709 was quantified by TaqMan assay (n = 3).  
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Figure 34. Relative abundance of miR-709 in an animal model of liver regeneration. 
(A) Livers from normal animals and mice that underwent partial hepatectomy (24, 36 and 
44 hours post-hepatectomy) were used to probe for miR-709 by Northern blotting using 
an LNA probe. The ribosomal RNA 5s was used as loading control. (B) miR-709 bands 
on blot were quantified by densitometry and results were normalized to 5s.   
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Figure 35. qPCR analysis of miR-709 and Rfx1 in an animal model of hepatocellular 
carcinoma. LapMyc male (tumor and adjacent normal; n=5) and LapMyc female mouse 
(n=2) livers (see legend of Figure 31 for details on genotype) were used to quantify 
mature miR-709 by TaqMan assay (left). Rfx-1 mRNA was analyzed on the same 
samples by qRT-PCR. *p<0.01 relative to normal male liver; #p<0.01 relative to normal 
female liver.  
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C.4. miR-709 inhibition elicits cell death 
Overall, the results suggested a role for miR-709 in cell proliferation. We 
questioned what would be the impact of inhibiting miR-709 function in quiescent versus 
actively dividing cells. The use of oligonucleotides complementary to the mature miRNA 
sequence (antagomiR or anti-miRs) has been a useful tool to downregulate miRNA 
activity and perform functional analysis. Thus, primary hepatocytes and Hepa1c1c cells 
were transfected with miR-709 inhibitors. 
 
Primary hepatocytes were transfected with 10, 17 and 25 nM miRIDIAN miR-709 
hairpin inhibitor or a control miRNA Cel-239b (Dharmacon). Neither antagomiR was 
toxic to cells, based on microscopic observation. Cells were harvested 24 hours later, and 
total RNA was isolated for analysis of miR-709 targets. Interestingly, levels of Rab11b 
and Ces1g barely increased even at the 25 nM dose (Figure 36). To confirm the data, a 
second anti-miR-709 from a different company (Ambion) was tested. Cells were 
transfected with 10 or 34 nM antagomiR, and RNA was isolated from cells 24 hours post-
transfection. Levels of miR-709 and snoRNA-202 (normalizer miRNA) were quantified 
using TaqMan assays. Surprisingly, the mirVana miRNA inhibitor against miR-709 
induced higher levels of miR-709 at a dose that was not toxic in cells that received the 
equivalent amount of Cel-239b (Figure 36). Levels of targets followed a similar pattern to 
those observed with the miRIDIAN inhibitor (data not shown). These data suggest that 
miR-709 has an important role in normal hepatocyte function and it cannot be 
downregulated.  
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Figure 36. miR-709, Rab11b, Ces1g and Rfx-1 expression in primary hepatocytes 
transfected with anti-miR-709. Primary hepatocytes were transfected with 10, 17 or 25 
nM of miRIDIAN miRNA inhibitor against miR-709 or control inhibitor, and harvested 
24 hours post-transfection (n=2; error bars represent standard deviation). Real time RT-
PCR analysis of Rab11b, Ces1g and Rfx-1. Cyclophillin A was used as normalizer gene. 
Primary hepatocytes were transfected with 10 or 34 nM of mirVana miRNA inhibitor 
against miR-709 or control inhibitor, and harvested 24 hours later. Mature miR-709 was 
quantified by TaqMan miRNA assay. Small nucleolar RNA 202 (snoRNA-202) was used 
as normalizer. 
 
We then analyzed the impact of inhibiting miR-709 in actively dividing cells. 
Hepa1c1c cells were transfected with amounts of antagomiR that were not toxic: 25 and 
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50 nM. Cell viability was then tested over time using an LDH assay. Inhibition of miR-
709 in hepatoma cells resulted in reduced viable cells at 50 nM concentration 72 hours 
post-transfection (Figure 37). As shown for quiescent cells, these data suggest that miR-
709 cannot be downregulated in actively dividing cells.  
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Figure 37. Cell viability assay in Hepa1c1c cells transfected with miR-709 inhibitor. 
Hepa1c1c cells were transfected with 25 or 50 nM of mirVana miRNA inhibitor against 
miR-709 or control inhibitor, and media was replaced 24 hours post-transfection. One-
hundred μl of media was collected 24, 48 and 72 hours post-transfection for LDH 
analysis. (n=3; error bars represent standard deviation). NT, not transfected.  
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C.5. Mature levels of miR-709 do not increase in db/db livers  
We have shown that miR-709 is upregulated in an animal model of type 2 
diabetes (Figure 11). To validate the microarray data and determine whether the increase 
in miR-709 is the mature form, Taqman assays were performed using total RNA. Figure 
38 shows that no difference was observed between db/db and normal mice, indicating 
that the increase in miR-709 detected in the chip array is likely to be precursor.  
 
 
Figure 38. Levels of mature miR-709 in livers of db/db mice. Normal and db/db  livers 
were used to quantify mature miR-709 by TaqMan assay (n=4). 
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DISCUSSION 
 
miRNAs play an important role in various cellular processes such as metabolism, 
development and apoptosis
154
. miRNAs are variably expressed across different tissues
155
, 
and the presence of abnormal profiles has been associated with various human 
disorders
154
. Despite emerging evidence of the role of miRNAs at regulating tissue 
function, there is a scarcity of information on their role at controlling the complex 
processes that take place in the liver. Therefore, we sought to identify miRNAs expressed 
in this tissue. By miRNA profiling between normal and db/db mice, we found that miR-
709 was upregulated in livers of diabetic mice. This has been recently confirmed in 
another study, in which many miRNAs were found dysregulated in type 2 diabetes
156
. We 
also observed that miR-709 was one of the most abundant miRNAs in murine liver, and 
recent studies have also showed high abundance of miR-709 in this tissue
97,145,157
. 
However, the increase of miR-709 in db/db mice livers could not be validated by Taqman 
PCR assay. This suggests that the increased miR-709 levels detected in db/db mice could 
potentially be pre-miR-709, given that the chip assay detects both, precursor and mature 
form, while the Taqman assay detects only mature miR-709. We have shown that the 
levels of miR-709 precursor are highly abundant in liver. It has been shown that miR-709 
has a function in the nucleus of fibroblasts, regulating levels of another miRNA (see next 
page). Thus, it is possible that in hepatocytes, the precursor also has a role in this cellular 
compartment, and the upregulation of miR-709 in db/db liver has implications for this 
unknown function.  
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 Given that miRNA are largely regulated by RNA polymerase II, we anticipated 
that their levels would change to repress/derepress genes that are not required during the 
physiological responses that take place between the fasted and refed conditions. 
Remarkably, of all 61 miRNAs differentially expressed, all but one were downregulated 
during the refed state, indicating that miRNA silence genes during fasting conditions, and 
their role as inhibitors of gene expression is more important in this state than during 
refeeding. Likewise, in the process of aging, it has been reported that hepatic miRNAs 
increase, but none decreases
97
. This phenomenon is also seen in aging-related Alzheimer 
disease in human brains
97
. Nevertheless, miR-709 was not influenced by the change in 
hepatic nutritional/hormonal changes, suggesting it is not a critical miRNA for the 
response that controls glucose, fatty acid and ketone body metabolism. 
 
Post-transcriptionally, miRNAs are processed through multiple steps and 
eventually form a linear miRNA:miRNA* duplex. Only one of these strands is selected to 
be incorporated into RISC, based on the thermodynamic instability and weaker base-
pairing at the 5’ end of the strands158,159. For some miRNAs, both strands can be loaded 
into RISC. For miR-709, the 3p has been reported as the active strand (data from the 
miRBase database). Our data confirms that this is also the case in liver, where the miR-
709-3p is the only strand used as guide.  
 
Mammalian miRNAs can target multiple genes from various pathways
160
. In 
murine liver, miR-709 has been reported to increase with aging
97
. Correlation of the 
predicted targets with a proteome and transcriptome profile of aging liver suggested that 
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this miRNA impacts genes in cytoskeletal function
97
. Thus, given the lack of knowledge 
on validated targets of miR-709, and its high abundance in liver, we sought to find its 
target genes. Our data indicates that miR-709 downregulates genes important in 
cytoskeleton structure, endocytosis and cellular adhesion pathways, as well as lipid 
metabolism. We confirmed that at least three of the identified genes, Rab11b, Ces1g and 
Pctp, are direct targets of miR-709 and that the absence of miR-709 binding site/s in the 
3’ UTR of these target genes leads to lack of inhibition. Downregulation of several 
targets, including Rab11b, was confirmed at the protein level in murine liver cells and the 
hepatoma cell line Hepa1c1c.  
 
There has been a lot of disparity between the predicted targets of a miRNA across 
various databases and the bona fide miRNA targets
161
. Hence, we compared the results 
from the microarray with the predicted targets of miR-709 across multiple databases to 
evaluate the extent of overlap with observed gene targets. Of the 6 databases used, we 
found that miRanda, miRWalk, DIANAmT and PICTAR5 had algorithms that best 
predicted miR-709 targets, with 60-70% of gene predictions being identified by 
microarray analysis. miRDB, TargetScan and RNA22 predicted less than 22% of the 
genes that were found downregulated in the microarray analysis. Hence, using multiple 
databases with good prediction score is a key to identifying miRNA targets. 
 
In the three dimensional structure of the liver, hepatocytes must be polarized with 
apical and basolateral membranes to be functional
12
. The two domains are separated by 
tight junctions
8
. Bile canaliculi are formed on the apical membrane of two adjacent 
106 
 
hepatocytes and bile acid transporters are confined to this area
8,143
. Based on the 
pathways targeted by miR-709, we hypothesized that this miRNA might regulate the 
capacity of hepatocytes to polarize and form functional bile canaliculi. Our data suggests 
that miR-709 does not affect the capacity of hepatocytes to maintain the apical-
basolateral polarity. Cells transfected with miR-709 and cultured in a sandwich culture 
model were able to form bile canaliculi and transport sodium fluorescein in a similar 
manner as Cel-239b-treated cells, implying that increased levels of mature miR-709 does 
not compromise liver organization. In addition, miR-709 sandwich cultures had similar 
survival times as Cel-239b-transfected cultures. Furthermore, primary hepatocytes 
cultured in a monolayer and transfected with miR-709 did not have faster rates of cell 
death over the course of 5 days relative to Cel-239b transfected hepatocytes (data not 
shown). Thus, miR-709 regulates genes that in a quiescent tissue do not affect cell 
survival or the capacity to maintain normal cellular architecture. Instead, our data 
suggests that miR-709 may be needed to facilitate cellular detachment from the 
extracellular matrix and cytoskeletal reorganization, processes that are needed after liver 
injury and repopulation, or during tumorigenesis. 
 
In fibroblasts, it was shown that miR-709 controls the maturation of miR-15a/16-
1
145
. In humans, this miRNA cluster is most commonly found deleted in chronic 
lymphocytic leukemia (CLL)
162
. The miR-15a/16-1 cluster of miRNAs has been shown 
to target the anti-apoptotic gene, Bcl-2
145
 as well as genes involved in cell cycle
163
. Under 
apoptotic stimuli, miR-709 changed its nuclear localization and was transported into the 
cytoplasm in fibroblasts
145
. This resulted in loss of inhibition of miR-15a/16-1 processing 
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and led to downregulation of Bcl-2
145
. However, Bcl-2 is not expressed in murine 
liver
164,165
 and therefore, it is unlikely that in this tissue miR-709 regulates apoptosis 
through the same mechanism. Furthermore, miR-709 has been shown to control 
expression of Brother Of the Regulator of Imprinted Sites (BORIS) in mouse testis
166
. 
BORIS is a testes-specific gene and an important regulator of DNA methylation and 
imprinting, and regulates epigenetic reprogramming during differentiation of germ 
cells
167
. However, this gene is not expressed in liver
167
. Thus, miR-709 may target 
distinct genes in different tissues.  
 
It has recently been reported that mature miR-709 is predominantly a nuclear 
miRNA in various cell lines and tissues
145
. The data were generated by analysis of RNA 
from nuclear and cytoplasmic fractions, as well as by transfection of L929 fibroblasts 
with a synthetic 5’-FAM-labeled miR-709 duplex probe145. Tamminga and colleagues 
have shown by in situ hybridization that miR-709 is predominantly located in the nucleus 
in testis
166
. Thus, we used a 3’-FAM-labeled synthetic miR-709 mimic to study the 
cellular localization of the mature miR-709 in liver. Our data indicates that mature miR-
709 is localized only in the cytoplasm of primary hepatocytes and Hepa1c1c cells under 
normal and metabolic stress culture conditions. It is possible that the location of mature 
miR-709 is different depending on the tissue, and in fibroblasts it is more nuclear than 
cytoplasmic. We have shown that in the liver, the precursor of miR-709 is significantly 
more abundant than the mature form, opposite to what is typically observed for the 
majority of miRNA. This has been reported to be the case across other mouse tissues, 
including brain, spinal cord, and heart
147
. The in situ hybridization study by Tamminga et 
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al.
166
, is consistent with higher levels of precursor in the nucleus, as the probe is likely to 
have detected the precursor and mature forms. The study showed the majority of the 
signal was present in the nucleus. Interestingly, miR-709 is not the only miRNA 
displaying this pattern: miR-690 and miR-720 also abundantly accumulate their 
precursors, while the mature form is scarce. The biological significance of the large 
accumulation of precursor, is currently unknown. 
 
We have also shown that in mouse models of cancer and liver regeneration, the 
levels of mature miR-709 increase significantly, suggesting a role in cell division. 
Supporting these observations, inhibition of miR-709 in hepatoma cells, leads to 
diminished cell survival. To determine the role of miR-709 in quiescent and actively 
dividing cells, antagomiRs were used to deplete endogenous levels of miR-709. 
Transfection of primary hepatocytes with antagomirs did not lead to a concomitant 
upregulation of miR-709 targets Rab11b and Ces1g. Instead, we observed a dose 
response increase in the expression of miR-709 as more antagomiR was used. This 
suggests that miR-709 may have vital functions in the liver and cannot be inhibited in 
hepatocytes, even though these cells seem to be able to tolerate a multiple-fold increase 
of mature miR-709. In Hepa1c1c cells, depletion of miR-709 resulted in a decrease in cell 
viability, which was not seen in primary hepatocytes at similar antagomiR concentration, 
suggesting that appropriate levels of this miRNA may be more critical for proliferating 
than quiescent cells.  
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The increase in miR-709 in liver tumors was accompanied by an increase in 
transcription of its host gene, Rfx1. Rfx1 is a transcription factor with transcription 
activation as well as repression activity. It is ubiquitously expressed, and is abundant in 
liver, with expression levels similar to genes implicated in metabolic functions such as 
insulin receptor substrate (Irs2), forkhead box protein O1 (Foxo1) or sirtuin 1 (Sirt1) 
(data not shown). Lack of Rfx1 results in early embryonic lethality
168
. Rfx1 inhibits its 
own expression, as well as genes implicated in cell proliferation such as PCNA and c-
Myc
151-153
. Although information on its function in liver is scarce, it has been recently 
shown that Rfx1 binds to the promoters of silent genes, such as Cdx2, and inhibit their 
activation by FoxA2. Cdx2 is a homeodomain transcription factor that determines 
intestinal epithelium differentiation and its ectopic expression has been associated with 
neoplastic processes. Indeed, Rfx1 downregulation is associated with esophageal 
carcinoma
169
. The same study showed that using siRNA to knockdown Rfx1, a maximum 
of 50% silencing could be obtained in a mouse epithelial cell line. As the mRNA levels 
were downregulated by the siRNA, Rfx1 gene transcription would increase
169
. We have 
observed that miR-709 downregulation with antagomiRs leads to an increase in miR-709 
levels. Thus, miR-709 and Rfx1 seem to work in a coordinated manner, and depletion of 
either one leads to feedback activation to compensate for the decrease in their levels. 
Perhaps miR-709 accumulates in the nucleus to regulate expression of its own host gene. 
Finally, it is possible that Rfx1 increases in our models of cell proliferation to inhibit 
expression of epithelial non-hepatic genes and retain liver function. 
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MiR-709 is not a conserved miRNA; the human ortholog is hsa-miR-1827, and 
shares the same seed sequence. Thus, an exciting study will be to determine whether the 
pathways regulated by hsa-miR-1827 are the same as those regulated by miR-709. Many 
of the predicted genes are the same or are within the same family. Thus, we predict that 
the hsa-miR-1827 will have a similar role to mmu-miR-709. It will be interesting to 
conduct studies in human samples and/or cell lines to establish its function in normal 
liver, as well as pathological conditions. 
 
In summary, miR-709 is most abundant in the pre-miR-709 form in the normal 
liver and is processed further to mature miR-709 only under conditions requiring cell 
division, such as cancer and liver regeneration. It is then that the mature miR-709 can 
bind to targets such as Rab11b, Ces1g, Pctp and Timp3 and aid in cellular regeneration 
perhaps by shutting down pathways that are not vital to the cell at that stage.  
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FUTURE DIRECTIONS 
 
Our study identified miR-709 as one of the most abundant miRNAs in murine 
liver and for the first time identified Rab11b, Ces1g and Pctp as direct targets. Recently, 
miR-709 has been found upregulated by 3.6-fold in db/db mice, an animal model of type 
2 diabetes mellitus
156
, by ~7-fold in livers of aging mice
97
, in X-ray irradiated mouse 
testis
166
, and during liver regeneration and hepatocellular carcinoma (this work). This 
suggests a role for this miRNA in the response of liver to stress conditions. Future in vivo 
studies are needed to address the physiological consequence of knocking down miR-709 
in type 2 diabetes liver, aging liver and hepatocellular carcinoma to study its role in these 
conditions. It is also intriguing that such high levels of precursor accumulate in the 
nucleus, which suggests an additional role in this compartment. miR-709 is not a 
conserved miRNA, and the ortholog miRNA in humans is hsa-mir-1827, which has the 
same seed sequence. Given the role of miR-709 in hepatocellular carcinoma and its 
potential role in liver regeneration, future studies should include characterizing its 
function in normal human liver, as well as analyzing human carcinoma samples to 
determine whether hsa-mir-1827 is dysregulated, and establishing its potential as a 
therapeutic target. 
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